

CITATION REPORT

List of articles citing

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

DOI: [10.1038/nature05945](https://doi.org/10.1038/nature05945)
Nature, 2007, 448, 561-6.

Source: <https://exaly.com/paper-pdf/42821774/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2186	Oncogene addiction: setting the stage for molecularly targeted cancer therapy. 2007 , 21, 3214-31		318
2185	Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. 2007 , 131, 1190-203		1810
2184	Cancer: broken genes in solid tumours. <i>Nature</i> , 2007 , 448, 545-6	50.4	15
2183	50 & 100 Years Ago. <i>Nature</i> , 2007 , 448, 546-546	50.4	
2182	Magnetism: managed mess. <i>Nature</i> , 2007 , 448, 546-7	50.4	1
2181	Translocation. 2007 , 7, 638-639		
2180	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. 2007 , 98, 1817-24		469
2179	Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. 2007 , 12, 501-13		154
2178	ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. 2007 , 12, 542-58		115
2177	The C. elegans EMAP-like protein, ELP-1 is required for touch sensation and associates with microtubules and adhesion complexes. 2008 , 8, 110		22
2176	Quantitative phosphoproteomics by mass spectrometry: past, present, and future. 2008 , 8, 4433-43		144
2175	Lung cancer epigenetics and genetics. 2008 , 123, 1-7		173
2174	High-resolution molecular cytogenetic analysis of Wilms tumors highlights diagnostic difficulties among small round cell kidney tumors. 2008 , 47, 845-52		12
2173	Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. 2008 , 22, 2091-6		38
2172	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. 2008 , 21 Suppl 2, S16-22		268
2171	Identification of ALK as a major familial neuroblastoma predisposition gene. <i>Nature</i> , 2008 , 455, 930-5	50.4	960
2170	Activating mutations in ALK provide a therapeutic target in neuroblastoma. <i>Nature</i> , 2008 , 455, 975-8	50.4	652

2169	Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. <i>Nature</i> , 2008 , 455, 967-70	50.4	658
2168	Oncogenic mutations of ALK kinase in neuroblastoma. <i>Nature</i> , 2008 , 455, 971-4	50.4	682
2167	Cancer: A ringleader identified. <i>Nature</i> , 2008 , 455, 883-4	50.4	11
2166	Theories of almost everything. <i>Nature</i> , 2008 , 455, 884-885	50.4	12
2165	Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that break in cancer-relevant genes. 2008 , 27, 3345-59		52
2164	EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. 2008 , 98, 1536-9		47
2163	Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. 2008 , 40, 722-9		666
2162	Molecular screening for new fusion genes in cancer. 2008 , 40, 685-6		31
2161	New susceptibility genes for ulcerative colitis. 2008 , 40, 686-8		12
2160	The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. 2008 , 14, 676-80		93
2159	The anaplastic lymphoma kinase in the pathogenesis of cancer. 2008 , 8, 11-23		673
2158	High-throughput kinase profiling as a platform for drug discovery. 2008 , 7, 391-7		181
2157	Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. 2008 , 99, 2349-55		180
2156	Chromosomal translocations in cancer. 2008 , 1786, 139-52		89
2155	Leukocyte tyrosine kinase functions in pigment cell development. 2008 , 4, e1000026		105
2154	Chromosomal abnormalities in cancer. 2008 , 359, 722-34		158
2153	EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. 2008 , 61, 163-9		143
2152	Gene expression profiling of non-small cell lung cancer. 2008 , 60, 313-24		50

2151	Molecular diversity of human breast cancer: clinical and therapeutic implications. 2008 , 10,	78
2150	Surviving breast cancer: can women expect to 'get back to normal'?. 2008 , 10,	78
2149	Identification of components of the ubiquitin system as targets for therapeutic intervention. 2008 , 10,	78
2148	Abnormal expression of p53 isoforms can be associated with poor survival in primary breast tumours. 2008 , 10,	78
2147	D133p53 isoform is a direct p53 target gene that modulates p53 tumour suppressor activity. 2008 , 10,	78
2146	Abstracts of the meeting of the Breast Cancer Campaign. London, United Kingdom. May 13, 2008. 2008 , 10 Suppl 2, L1-P95	
2145	Primary ductal carcinoma in situ mammosphere formation: importance of the epidermal growth factor and Notch receptor signalling pathways. 2008 , 10,	78
2144	What is the psychological impact of mammographic screening on younger women with a family history of breast cancer? Findings from a prospective cohort study (PIMMS). 2008 , 10,	78
2143	Accurate prediction of BRCA1 and BRCA2 heterozygous genotypes using expression profiling of lymphocytes after irradiation-induced DNA damage. 2008 , 10,	78
2142	The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. 2008 , 10,	78
2141	Health inequalities in breast cancer screening. 2008 , 10,	2
2140	Inhibition of apoptosis by Notch signalling in breast epithelial cells. 2008 , 10,	78
2139	Urinary and serum biomarkers of phytoestrogen exposure are not associated with breast cancer risk in the European Prospective into Cancer Norfolk study. 2008 , 10,	78
2138	Quantitative proteomics reveals proteins associated with radiotherapy resistance in breast cancer cells. 2008 , 10,	1
2137	Regulation of cyclin D1 by the BRCA1/BARD1 complex. 2008 , 10,	78
2136	Investigation of the roles of novel apoptosis-controlling genes in breast cancer. 2008 , 10,	78
2135	Proteomic screening of 725 antibodies simultaneously using antibody microarray technology to identify proteins associated with radiotherapy resistance in breast cancer cells. 2008 , 10,	78
2134	De novo expression of $\alpha 5 \beta 1$ integrin by myoepithelial cells in ductal carcinoma in situ may be an important marker of disease progression. 2008 , 10,	2

2133	Activation of TGF-beta signalling in breast cancer metastatic cells. 2008, 10,	1
2132	Prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. 2008, 10,	4
2131	Development of functional assays for BRCA1 missense mutations. 2008, 10,	78
2130	Downregulation of 15-hydroxyprostaglandin dehydrogenase in hormone-resistant breast cancer. 2008, 10,	78
2129	Dietary patterns across the life course, mammographic density and implications for breast cancer: results from a British prospective cohort. 2008, 10,	78
2128	Identification and definition of novel clinical phenotypes of breast cancer through consensus derived from automated clustering methods. 2008, 10,	5
2127	Association of MMP8 gene variation with breast cancer prognosis. 2008, 10,	1
2126	Characterization of a cytoskeletal signaling pathway underpinning CD44-initiated, integrin-mediated adhesion of breast cancer cells to bone marrow endothelium. 2008, 10,	1
2125	Suppression of the NF- κ B cofactor Bcl3 inhibits mammary epithelial cell apoptosis and, in breast tumours, correlates with poor prognosis. 2008, 10,	1
2124	Prospective Study of Outcome in Sporadic versus Hereditary Breast Cancer: pros and cons of running a cohort study. 2008, 10,	78
2123	Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1. 2008, 10,	78
2122	Matrix metalloproteinase-8 is a regulator of the clinical aggressiveness of mammary tumours. 2008, 10,	78
2121	Two functionally distinct epithelial progenitors exist within the luminal cell compartment of the mouse mammary gland. 2008, 10,	1
2120	Chromosome translocations in breast cancer. 2008, 10,	78
2119	TARGIT: an international trial of intraoperative versus external beam radiotherapy. 2008, 10,	78
2118	C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target. 2008, 10,	78
2117	Insulin-like growth factor binding protein 3 modulates epidermal growth factor (EGF)-induced growth of breast epithelial cells by altering EGF receptor internalization. 2008, 10,	1
2116	Lineage commitment in mammary epithelium is regulated by type 2 cytokines and Stat6. 2008, 10,	0

2115	A novel role for C-terminal binding proteins in the regulation of mitotic fidelity in breast cancer cells. 2008 , 10,	78
2114	Bevacizumab resistance in breast cancer: are neuropilins the key?. 2008 , 10,	3
2113	Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer. 2008 , 10,	78
2112	Assessment of angiogenesis in the hyperplasia preinvasive, invasive breast carcinoma sequence. 2008 , 10,	78
2111	Role of poly(ADPribosyl)ation of CTCF in cancer and normal breast cells. 2008 , 10,	78
2110	Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. 2008 , 10,	78
2109	Proapoptotic protein Bid is regulated by phosphorylation during anoikis and the cell cycle. 2008 , 10,	78
2108	Association of gene variants in the TGF-beta signalling pathways with invasive breast cancer risk. 2008 , 10,	78
2107	p53 Δ isoform modulates differentially p53 transcriptional activity in response to stress. 2008 , 10,	78
2106	Investigation of immunoregulatory mechanisms relating to poor surgical wound healing and breast cancer recurrence. 2008 , 10,	78
2105	Cytochrome P450 modulates the therapeutic actions of tamoxifen, as evidenced in novel breast cancer models. 2008 , 10,	78
2104	Cellular localization of the proto-oncogenic p53 inhibitor AGR2 protein in breast cancer. 2008 , 10,	78
2103	Exploring the breast cancer experiences, needs and preferences of women aged 70 years and over: a study in progress. 2008 , 10,	78
2102	Diagnosed with breast cancer whilst on a family history screening programme: an exploratory qualitative study. 2008 , 10,	1
2101	TSC22 in mammary gland development and breast cancer. 2008 , 10,	78
2100	Adherence to hormone therapy in a chemoprevention randomised trial. 2008 , 10,	78
2099	Investigation into the molecular mechanism of the antiapoptotic functions of CTCF in breast cancer cells using a proteomics approach. 2008 , 10,	78
2098	Living with genetic risk of breast cancer: what have we learned?. 2008 , 10,	78

2097	MCPH1, a potential predictor for response to cancer chemotherapy. 2008 , 10,	78
2096	Homeopathy service in an NHS hospital breast cancer clinic: outcome study. 2008 , 10,	3
2095	TopBP1 contains transcriptional regulatory domains and regulates gene pathways involved in breast cancer. 2008 , 10,	78
2094	Identification of proteins associated with radiotherapy resistance in breast cancer cells: a combined proteomic and microarray screening approach. 2008 , 10,	78
2093	PARP-1 inhibitor monotherapy and combination therapy in a preclinical mouse model of Brca2 mutant breast cancer. 2008 , 10,	78
2092	Modelling estrogen receptor alpha-positive breast cancer by transformation of normal human mammary epithelial cells. 2008 , 10,	78
2091	Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer. 2008 , 10,	3
2090	Identification and role of migration stimulating factor isoforms in breast carcinomas. 2008 , 10,	78
2089	Reelin expression in breast tumours is associated with increased survival and is controlled by promoter methylation. 2008 , 10,	0
2088	Understanding and exploiting changes in O-linked glycosylation in breast cancer. 2008 , 10,	78
2087	Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes. 2008 , 10,	78
2086	High-throughput optical proteomics and breast cancer patient profiling: novel applications to individualise prognosis and treatment. 2008 , 10,	78
2085	Chemotherapy-induced modulation of [18F]Fluoro-2-deoxy-D-glucose incorporation at the tumour cell level. 2008 , 10,	78
2084	Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis. 2008 , 10,	2
2083	Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor. 2008 , 10,	78
2082	Detection of gene amplification in matched tumour and plasma DNA from breast cancer patients by quantitative PCR. 2008 , 10,	1
2081	CD44 signalling increases cathepsin K and MT1MMP expression to potentiate breast cancer cell invasion through collagen I. 2008 , 10,	1
2080	Identification of genes involved in the formation of lymph node metastasis from human tumour xenograft models of breast cancer. 2008 , 10,	78

2079	Role of the Hsp90 cochaperone, FKBPL, in oestrogen receptor signalling and breast cancer growth and survival. 2008 , 10,	1
2078	Lymphovascular invasion in breast cancer: improved methods of detection and clinical significance. 2008 , 10,	78
2077	Brk expression may affect the differentiation status of breast cancer cells. 2008 , 10,	78
2076	Role of CLEVER-1 in breast cancer metastasis. 2008 , 10,	78
2075	Actions of IGF-I are differentially regulated by fatty acids in normal and breast cancer epithelial cells. 2008 , 10,	78
2074	Interactions between BRCA2 protein and the meiosis-specific recombinase DMC1. 2008 , 10,	78
2073	ZNF366 is a novel corepressor for estrogen receptor alpha that mediates its effects through interaction with CtBP. 2008 , 10,	78
2072	Cambridge Breast Intensity Modulated Radiotherapy Trial: dosimetry results for 1,139 patients. 2008 , 10,	78
2071	Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?. 2008 , 10,	78
2070	Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity. 2008 , 10,	1
2069	Topoisomerase II expression as a determinant of chromosomal radiosensitivity and possible susceptibility in breast cancer. 2008 , 10,	78
2068	RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours. 2008 , 10,	78
2067	Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid. 2008 , 10,	78
2066	Stromal fibroblasts with nuclear E-catenin are present within breast tumours and increase proliferation and invasion of epithelial breast cancer cells. 2008 , 10,	78
2065	Altered myoepithelial cell expression and function in cancer-containing breasts. 2008 , 10,	78
2064	NRG1 is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. 2008 , 10,	1
2063	An exploration of the management of menopausal symptoms for women with a diagnosis of breast cancer: lay and professional experiences and expectations. 2008 , 10,	1
2062	Exploring the acceptability of, and preferences for, an ongoing support network for known BRCA1 and BRCA2 mutation carriers. 2008 , 10,	78

2061	Breast cancer and environmental risk factors: an appraisal of the scientific evidence. 2008 , 10,	4
2060	From association to cause: fine mapping of the TNRC9 gene region, a novel susceptibility locus identified in the first genome-wide association study for breast cancer. 2008 , 10,	1
2059	Inhibitor of apoptosis proteins as a therapeutic target in breast cancer. 2008 , 10,	78
2058	Discrepancies and challenge of ductal carcinoma in situ for health professionals. 2008 , 10,	78
2057	'The sooner the better' or 'too much too soon'? A pilot prospective longitudinal study to evaluate quality of life and body image following immediate latissimus dorsi breast reconstruction. 2008 , 10,	78
2056	Coactivation of estrogen receptor alpha by the DEAD-box RNA helicases p68 and p72 and its role in breast cancer. 2008 , 10,	78
2055	Multicentre study of CASP8 polymorphisms in breast cancer. 2008 , 10,	78
2054	Investigating h-Prune activation of Wnt signalling in breast cancer. 2008 , 10,	78
2053	Food choice and phytoestrogen consumption in women previously treated for postmenopausal breast cancer. 2008 , 10,	78
2052	'More positive about mammography' Reactions of women to a false positive recall: a qualitative study of women at risk of familial breast cancer. 2008 , 10,	78
2051	Regulation of estrogen receptor beta by 5' untranslated regions in breast carcinogenesis. 2008 , 10,	78
2050	Expression analysis of novel biomarkers for breast cancer. 2008 , 10,	2
2049	The QUEST study: a multicentre randomised trial to assess the impact of the type and timing of breast reconstruction on quality of life following mastectomy. 2008 , 10,	78
2048	Use of BRCA1 protein:protein interactions to classify cancer risk. 2008 , 10,	2
2047	Lung cancer. 2008 , 359, 1367-80	1920
2046	High-content analysis of cancer genome DNA alterations. 2008 , 18, 68-72	13
2045	Recurrent gene fusions in prostate cancer. 2008 , 8, 497-511	554
2044	EML4-ALK fusion lung cancer: a rare acquired event. 2008 , 10, 298-302	201

2043	A mouse model for EML4-ALK-positive lung cancer. 2008 , 105, 19893-7	413
2042	From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. 2008 , 4, 569-77	24
2041	Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. 2008 , 68, 4971-6	351
2040	The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. 2008 , 68, 8899-907	47
2039	CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. 2008 , 68, 7156-64	52
2038	EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. 2008 , 3, 13-7	387
2037	EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. 2008 , 14, 4275-83	774
2036	Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. 2008 , 14, 6618-24	404
2035	Starvation induces genomic rearrangements and starvation-resilient phenotypes in yeast. 2008 , 25, 310-8	37
2034	Evaluation of paired-end sequencing strategies for detection of genome rearrangements in cancer. 2008 , 4, e1000051	63
2033	Defining a candidate lung cancer gene. 2008 , 100, 1564-5	3
2032	Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. 2008 , 8, 774-83	17
2031	Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. 2008 , 68, 3389-95	349
2030	ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. 2008 , 112, 2965-8	71
2029	Chromosomal translocations: revisited yet again. 2008 , 112, 2183-9	113
2028	[Malignant lymphoma: diagnostic approach. 1. Pathological diagnosis]. 2008 , 97, 1537-45	0
2027	Divide and conquer: progress in the molecular stratification of cancer. 2009 , 50, 464-73	4
2026	The Cancer Genome. 2009 , 24, 17-22	

2025	Inhibition of ALK signaling for cancer therapy. 2009 , 15, 5609-14	125
2024	Integration of molecular profiling into the lung cancer clinic. 2009 , 15, 5317-22	73
2023	Increased PEA3/E1AF and decreased Net/Elk-3, both ETS proteins, characterize human NSCLC progression and regulate caveolin-1 transcription in Calu-1 and NCI-H23 NSCLC cell lines. 2009 , 30, 1433-42	23
2022	Chromosomal translocations induced at specified loci in human stem cells. 2009 , 106, 10620-5	166
2021	Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. 2009 , 7, 1466-76	242
2020	Gene fusions and RNA trans-splicing in normal and neoplastic human cells. 2009 , 8, 218-22	67
2019	ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. 2009 , 4, 1450-4	244
2018	Modeling the molecular consequences of unbalanced translocations in cancer: lessons from acute lymphoblastic leukemia. 2009 , 8, 2175-84	12
2017	Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. 2009 , 94, 897-900	33
2016	Inhibition of G(1) to S phase progression by a novel zinc finger protein P58(TFL) at P-bodies. 2009 , 7, 880-9	20
2015	Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. 2009 , 69, 3937-46	86
2014	GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. 2009 , 8, 2811-20	84
2013	Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins. 2009 , 5, e1000552	63
2012	EML4-ALK: honing in on a new target in non-small-cell lung cancer. 2009 , 27, 4232-5	258
2011	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. 2009 , 15, 7502-7509	115
2010	In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. 2009 , 132, 500-5	21
2009	Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. 2009 , 27, 5650-9	103
2008	Chimeric transcript discovery by paired-end transcriptome sequencing. 2009 , 106, 12353-8	275

2007	Mutation-associated fusion cancer genes in solid tumors. 2009 , 8, 1399-408	44
2006	Pathogenesis of lung cancer signalling pathways: roadmap for therapies. 2009 , 33, 1485-97	114
2005	Highlights From: The 13th World Conference on Lung Cancer San Francisco, CA July 31-August 4, 2009. 2009 , 10, 317-321	
2004	ErbBs in lung cancer. 2009 , 315, 557-71	57
2003	Cancer gene discovery in mouse and man. 2009 , 1796, 140-61	8
2002	Translocations in epithelial cancers. 2009 , 1796, 201-15	24
2001	Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK). 2009 , 36, S36-41	14
2000	Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. 2009 , 36, S27-35	34
1999	Off-target decoding of a multitarget kinase inhibitor by chemical proteomics. 2009 , 10, 1163-74	14
1998	A gene-alteration profile of human lung cancer cell lines. 2009 , 30, 1199-206	100
1997	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. 2009 , 115, 1723-33	598
1996	Loss of dystrophin and the microtubule-binding protein ELP-1 causes progressive paralysis and death of adult <i>C. elegans</i> . 2009 , 238, 1878-86	5
1995	Lung cancer biology: a genetic and genomic perspective. 2009 , 11, 263-9	13
1994	Anaplastic lymphoma kinase: an oncogene for tumor vaccination. 2009 , 87, 669-77	7
1993	TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. 2009 , 217, 65-72	70
1992	Fusion genes and chromosome translocations in the common epithelial cancers. 2010 , 220, 244-54	85
1991	A reason why the ERBB2 gene is amplified and not mutated in breast cancer. 2009 , 9, 5	10
1990	Finding exclusively deleted or amplified genomic areas in lung adenocarcinomas using a novel chromosomal pattern analysis. 2009 , 2, 43	6

1989	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. 2009 , 22, 508-15		380
1988	Transcriptome sequencing to detect gene fusions in cancer. <i>Nature</i> , 2009 , 458, 97-101	50.4	709
1987	The cancer genome. <i>Nature</i> , 2009 , 458, 719-24	50.4	2272
1986	Complex landscapes of somatic rearrangement in human breast cancer genomes. <i>Nature</i> , 2009 , 462, 1005-10	50.4	684
1985	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. 2009 , 27, 1005-11		63
1984	Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. 2009 , 8, 709-23		259
1983	Lessons from the lung for targeted anticancer drugs. 2009 , 8, 758-9		2
1982	Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. 2009 , 28, 3296-306		33
1981	Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin. 2009 , 28, 4095-104		48
1980	DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure. 2009 , 100, 1336-42		26
1979	Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. 2009 , 9, 331-56		168
1978	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009 , 27, 4247-53		1462
1977	Chapter 23 A Path to Innovation: Gene Knockouts Model New Drug Action. 2009 , 475-497		0
1976	Commonality but diversity in cancer gene fusions. 2009 , 137, 391-5		58
1975	Integrative genomic approaches to understanding cancer. 2009 , 1790, 478-84		6
1974	Oncogenic gene fusions in epithelial carcinomas. 2009 , 19, 82-91		60
1973	Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. 2009 , 40, 1152-8		157
1972	Recent and new targets for small molecule anti-cancer agents. 2009 , 6, e1-e40		7

1971	KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. 2009 , 15, 3143-9	590
1970	EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. 2009 , 174, 661-70	261
1969	ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. 2009 , 48, 3600-9	27
1968	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. 2009 , 15, 5216-23	560
1967	Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase. 2009 , 20, 364-72	7
1966	ALK-positive diffuse large B-cell lymphoma with the t(2;17)(p23;q23). 2009 , 17, 172-7	14
1965	Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. 2009 , 33, 984-91	277
1964	Sequence-based advances in the definition of cancer-associated gene mutations. 2009 , 21, 47-52	9
1963	[Molecular-targeted therapy in the developing stage. 1) VEGFR-TKI and EGFR-TKI]. 2009 , 98, 1887-93	
1962	Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen. 2009 , 94, 1440-4	15
1961	The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. 2009 , 94, 1307-11	15
1960	Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. 2009 , 4, 1202-11	58
1959	Anaplastic lymphoma kinase: signalling in development and disease. 2009 , 420, 345-61	326
1958	Unraveling ALK signaling through phosphoproteomics. 2009 , 113, 2615-6	2
1957	Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. 2009 , 4, 787-91	25
1956	A doublecortin containing microtubule-associated protein is implicated in mechanotransduction in <i>Drosophila</i> sensory cilia. 2010 , 1, 11	44
1955	The genomics of lung adenocarcinoma: opportunities for targeted therapies. 2010 , 1, 1200-10	64
1954	Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. 2010 , 11, 851-64	40

1953	Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. 2010 , 5, 420-7	40
1952	Lung cancer genomic signatures. 2010 , 5, 1673-91	24
1951	Incidentally proven pulmonary "ALKoma". 2010 , 49, 603-6	4
1950	[Discovery of EML4-ALK, a new gene responsible for lung cancer, and the development of molecular targeted therapy]. 2010 , 99, 837-41	
1949	Secreted form of EphA7 in lung cancer. 2010 , 36,	2
1948	ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. 2010 , 95, 509-13	78
1947	Molecular origins of lung cancer: prospects for personalized prevention and therapy. 2010 , 5, S207-13	4
1946	EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas. 2010 , 1, 271-275	10
1945	Lymphocyte homing and the dissemination of lymphoid malignancies. 2010 , 293-306	
1944	Treatment of lung cancer with an ALK inhibitor after EML4-ALK fusion gene detection using endobronchial ultrasound-guided transbronchial needle aspiration. 2010 , 5, 2041-3	20
1943	Abstracts. 2010 , 5, S214-S257	
1942	Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?. 2010 , 8, 822-32	31
1941	EML4/ALK and ras inhibitors. 2010 , 5, S495-6	
1940	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. 2010 , 17, 889-97	266
1939	Fusion genes in epithelial neoplasia. 2010 , 63, 4-11	5
1938	Systemische Therapie des nichtkleinzelligen Bronchialkarzinoms. 2010 , 3, 113-117	
1937	Lungenkrebs: vom Gen zur Therapie. 2010 , 3, 81-86	
1936	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. 2010 , 28, 4769-77	214

1935	[Dangerous liaisons in prostate cancer. Clinical and biological implications of recurrent gene fusions]. 2010 , 31 Suppl 2, 121-5	6
1934	The benefits of molecular pathology in the diagnosis of musculoskeletal disease : part I of a two-part review: soft tissue tumors. 2010 , 39, 105-15	9
1933	Lung cancer [ASCO 2010]. 2010 , 3, 172-176	0
1932	Impact of biomarkers on non-small cell lung cancer treatment. 2010 , 5, 5-17	14
1931	Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. 2010 , 11, 36-44	40
1930	Molecular testing in lung cancer: the time is now. 2010 , 12, 335-48	18
1929	Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. 2010 , 29, 73-93	39
1928	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. 2010 , 29, 49-60	164
1927	Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications. 2010 , 29, 15-21	87
1926	Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Src1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2. 2010 , 11, 125-41	4
1925	Genomic rearrangements in inherited disease and cancer. 2010 , 20, 222-33	118
1924	Fluorescence in situ hybridization analysis with a tissue microarray: 'FISH and chips' analysis of pathology archives. 2010 , 60, 543-50	26
1923	The 2010 Meeting of the American Society of Clinical Oncology. 2010 , 11, 303-310	1
1922	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. 2010 , 15, 88-97	57
1921	Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. 2010 , 80, 613-23	69
1920	Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. 2010 , 197, 130-41	26
1919	Somatic mutations of signaling genes in non-small-cell lung cancer. 2010 , 203, 7-15	36
1918	ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. 2010 , 18, 548-51	188

1917	Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. 2010 , 49, 509-17		20
1916	Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. 2010 , 49, 1062-9		161
1915	ROS receptor tyrosine kinase: a new potential target for anticancer drugs. 2011 , 31, 794-818		37
1914	Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. 2010 , 277, 301-8		355
1913	Identification of transforming activity of free fatty acid receptor 2 by retroviral expression screening. 2010 , 101, 54-9		27
1912	Identification of the transforming activity of Indian hedgehog by retroviral expression screening. 2010 , 101, 60-4		3
1911	Molecular pathogenesis of peripheral neuroblastic tumors. 2010 , 29, 1566-79		73
1910	ALK fusion genes in children with atypical myeloproliferative leukemia. 2010 , 24, 1197-200		34
1909	The mutation spectrum revealed by paired genome sequences from a lung cancer patient. <i>Nature</i> , 2010 , 465, 473-7	50.4	403
1908	Translating cancer research into targeted therapeutics. <i>Nature</i> , 2010 , 467, 543-9	50.4	269
1907	Nanocolonies and diagnostics of oncological diseases associated with chromosomal translocations. 2010 , 75, 1667-91		2
1906	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. 2010 , 16, 793-8		382
1905	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. 2010 , 10, 241-53		410
1904	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. 2010 , 10, 760-74		802
1903	Advances in understanding cancer genomes through second-generation sequencing. 2010 , 11, 685-96		890
1902	The current status of targeted therapy for non-small cell lung cancer. 2010 , 40, 611-8		17
1901	Refining the treatment of advanced nonsmall cell lung cancer. 2010 , 1, 9-22		1
1900	Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. 2010 , 1, 10		1

1899	Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling. 2010 , 5, e13470	29
1898	Molecular Biology of Lung Cancer. 2010 , 50, 329-341	
1897	Biomarkers are here to stay for clinical research and standard care. 2010 , 5, 1113-5	5
1896	Prevention of Lung Cancer: Future Perspective with Natural Compounds. 2010 , 69, 1	5
1895	ChimerDB 2.0--a knowledgebase for fusion genes updated. 2010 , 38, D81-5	70
1894	A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells. 2010 , 16, 1156-66	30
1893	Lung cancer: multidisciplinary approach for management: cell and molecular biology assembly contribution to the celebration of 20 years of the ERS. 2010 , 35, 717-20	8
1892	Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. 2010 , 7, 367-80	84
1891	Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. 2010 , 38, 6985-96	36
1890	Targeted therapies for non-small cell lung cancer: an evolving landscape. 2010 , 9, 1931-44	65
1889	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. 2010 , 363, 1727-33	622
1888	[Molecular characteristics of lung cancer]. 2010 , 97, 1323-35	3
1887	[Search for new genes involved in breast tumorigenesis by "Omics" analysis]. 2010 , 97, 1365-80	
1886	EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. 2010 , 16, 4938-45	135
1885	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. 2010 , 28, 4616-20	277
1884	Clinical implications of the cancer genome. 2010 , 28, 5219-28	156
1883	A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. 2010 , 16, 1561-71	364
1882	The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies. 2010 , 95, 47-61	27

1881	A therapeutic target for smoking-associated lung cancer. 2010 , 2, 62ps56	18
1880	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. 2010 , 70, 10038-43	264
1879	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. 2010 , 16, 5581-90	284
1878	Update on nonsmall cell lung cancer. 2010 , 19, 173-85	14
1877	Progress in cancer chemotherapy with special stress on molecular-targeted therapy. 2010 , 40, 855-62	15
1876	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. 2010 , 2, 62ra93	646
1875	Advances in target therapy for lung cancer. 2010 , 40, 101-6	58
1874	The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. 2010 , 106, 93-133	97
1873	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010 , 363, 1693-703	3577
1872	EGF receptor in lung cancer: a successful story of targeted therapy. 2010 , 10, 1577-87	12
1871	Personalized medicine for non-small-cell lung cancer. 2010 , 10, 1601-11	10
1870	Redefining disease. 2010 , 10, 584-94	11
1869	Mortality in the randomized, controlled lung intergroup trial of isotretinoin. 2010 , 3, 738-44	9
1868	Systems Pharmacology in Cancer. 2010 , 377-397	
1867	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. 2010 , 70, 9827-36	164
1866	Oropharyngeal cancer, human papilloma virus, and clinical trials. 2010 , 28, 1-3	65
1865	The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer. 2010 , 13, 117-25	4
1864	Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. 2010 , 115, 4061-70	22

1863	Chromosomal and genomic changes in lung cancer. 2010 , 4, 100-6	29
1862	New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. 2010 , 9, 2986-95	86
1861	[Implications of ALK (anaplastic lymphoma kinase) in oncohematology]. 2010 , 97, 991-6	0
1860	Individualisierte Therapie für Patienten mit fortgeschrittenen Lungenkarzinomen. 2010 , 31, 79-87	
1859	Clinical year in review I: interstitial lung disease, pulmonary vascular disease and venous thromboembolism, diagnostic imaging, and lung cancer. 2010 , 7, 297-304	
1858	Lung cancer therapeutics that target signaling pathways: an update. 2010 , 4, 631-45	19
1857	What we learn from transformation suppressor genes: lessons from RECK. 2010 , 6, 1105-16	14
1856	Novel agents in the management of lung cancer. 2010 , 17, 4291-325	16
1855	Highlights of the 2nd European Lung Cancer Conference. 2010 , 10, 1023-5	1
1854	Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. 2010 , 4, 499-508	5
1853	[Molecular abnormalities in lymphomas]. 2010 , 97, 1347-64	3
1852	A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress. 2010 , 70, 6325-35	26
1851	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. 2010 , 11, 2363-89	18
1850	[Pretreatment molecular biology analysis on small size biopsies]. 2010 , 30, 67-72	2
1849	Diagnosis of Nodal Peripheral T-Cell Lymphomas. 2010 , 3, 955-88	1
1848	Ciblage thérapeutique du cancer pulmonaire non à petites cellules (CPNPC) : (encore) des promesses?. 2010 , 2, 524-526	
1847	Targeted Therapies in Lung Cancer. 2010 , 3, 71-82	25
1846	Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. 2010 , 49, 6813-25	117

1845	Nonrandom Chromosome Abnormalities in Cancer: An Overview. 2010 , 25-43	4
1844	Tumors of the Lung. 2010 , 415-428	
1843	Cytogenetics and genetics of human cancer: methods and accomplishments. 2010 , 203, 102-26	28
1842	Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. 2010 , 69, 361-4	14
1841	Cytogenomics of cancers: from chromosome to sequence. 2010 , 4, 309-22	20
1840	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?. 2010 , 7, 401-14	205
1839	FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. 2010 , 11, R104	121
1838	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. 2010 , 9, 188	227
1837	Management of patients with advanced non-small cell lung cancer: current and emerging options. 2010 , 70, 167-79	17
1836	Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. 2010 , 115, 3314-9	93
1835	Integrative analysis of the melanoma transcriptome. 2010 , 20, 413-27	216
1834	Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature? Reply. 2010 , 41, 615-616	
1833	Antibody to cytokeratin (CK8/CK18) is not derived from CAM5.2 clone, and anticytokeratin CAM5.2 (Becton Dickinson) is not synonymous with the antibody (CK8/CK18). 2010 , 41, 616-7; author reply 617	10
1832	Immunohistochemical surrogates for genetic alterations of CCDN1, PML, ALK, and NPM1 genes in lymphomas and acute myeloid leukemia. 2010 , 23, 417-31	8
1831	All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK. 2010 , 297, 220-5	11
1830	Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy. 2010 , 299, 81-94	44
1829	Parameters for individualizing systemic therapy in non-small cell lung cancer. 2010 , 13, 196-204	12
1828	Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. 2010 , 46, 2166-77	62

1827	The biology and treatment of EML4-ALK non-small cell lung cancer. 2010 , 46, 1773-80	417
1826	The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. 2010 , 46, 2357-68	48
1825	Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models. 2010 , 52, 352-8	19
1824	Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. 2010 , 63, 1066-70	108
1823	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. 2010 , 28, 4953-60	296
1822	The molecular pathology of cancer. 2010 , 7, 251-65	182
1821	Activity of crizotinib in patients with non-small cell lung cancer. 2010 , 7, 443	2
1820	ALK inhibitors: a major step in the right direction. 2010 , 7, 444	
1819	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. 2010 , 36 Suppl 3, S21-9	97
1818	EML4-ALK fusion in lung. 2010 , 176, 1552-3; author reply 1553-4	13
1817	Lung cancer in never smokers: a new hot area of research. 2010 , 11, 304-5	21
1816	Genetics and genomics of neuroblastoma. 2010 , 155, 65-84	65
1815	Crizotinib--latest champion in the cancer wars?. 2010 , 363, 1760-2	56
1814	Receptor Tyrosine Kinases. 119-213	
1813	EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. 2010 , 363, 1734-9	940
1812	Chromosomal aberrations in solid tumors. 2010 , 95, 55-94	19
1811	Deciding priorities in Pharma. 2010 , 12 Suppl 4, S21	
1810	Principles of Clinical Cancer Genetics. 2010 ,	2

1809	High-throughput analysis of chromosome translocations and other genome rearrangements in epithelial cancers. 2010 , 2, 19	1
1808	Common gene rearrangements in prostate cancer. 2011 , 29, 3659-68	231
1807	Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. 2011 , 11, 1677-87	23
1806	Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction. 2011 , 15, 353-9	8
1805	Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703. 2011 , 15, 351-3	29
1804	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. 2011 , 29, 2046-51	509
1803	A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. 2011 , 39, e100	82
1802	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. 2011 , 108, 7535-40	445
1801	Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. 2011 , 13, 504-13	68
1800	Classification histologique des cancers broncho-pulmonaires non \square petites cellules. 2011 , 3, 295-301	0
1799	Evaluation and treatment of patients with non-small cell lung cancer. 2011 , 95, 1041-54	20
1798	Rapid high-resolution mapping of balanced chromosomal rearrangements on tiling CGH arrays. 2011 , 13, 621-33	21
1797	A decade of advances in treatment for advanced non-small cell lung cancer. 2011 , 32, 839-51	50
1796	Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. 2011 , 13, 704-15	34
1795	Molecular biology of lung cancer: clinical implications. 2011 , 32, 703-40	156
1794	Biomarkers in lung cancer. 2011 , 6-17	
1793	Quantifying factors for the success of stratified medicine. 2011 , 10, 817-33	72
1792	Lung cancer in 2010: One size does not fit all. 2011 , 8, 68-70	44

1791	CD44-SLC1A2 gene fusions in gastric cancer. 2011 , 3, 77ra30	43
1790	Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer. 2011 , 72, 32-8	17
1789	Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. 2011 , 72, 309-15	94
1788	Lung cancer in never smokers: change of a mindset in the molecular era. 2011 , 72, 9-15	65
1787	Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. 2011 , 74, 118-23	35
1786	The search for improved systemic therapy of non-small cell lung cancer--what are today's options?. 2011 , 72, 265-70	17
1785	Fifth Educational Symposium of the Spanish Lung Cancer Group: report on the Molecular Biology Workshop. 2011 , 74, 535-43	1
1784	Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: a case report. 2011 , 73, 375-8	4
1783	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. 2011 , 5, 471-85	129
1782	Personalized medicine in lung cancer: what we need to know. 2011 , 8, 661-8	118
1781	Tumours. 2011 , 531-705	
1780	Role of genotyping in non-small cell lung cancer treatment: current status. 2011 , 71, 2231-46	17
1779	9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors. 2011 , 54, 6286-94	62
1778	Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. 2011 , 365, 158-67	8
1777	Carbon nanotubes and pleural damage: perspectives of nanosafety in the light of asbestos experience. 2011 , 6, P1-17	39
1776	The potential for crizotinib in non-small cell lung cancer: a perspective review. 2011 , 3, 279-91	62
1775	The BATTLE to personalize lung cancer prevention through reverse migration. 2011 , 4, 962-72	40
1774	Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. 2011 , 71, 4920-31	174

1773	Oncologie thoracique. 2011 , 3, 158-165	
1772	[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments]. 2011 , 67 Suppl 1, S36-40	1
1771	Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. 2011 , 4, 59-70	8
1770	Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. 2011 , 13, 1-11	51
1769	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. 2011 , 1, 608-25	108
1768	Crizotinib. 2011 , 10, 897-8	82
1767	Oncologie thoracique. 2011 ,	
1766	The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. 2011 , 7, 519-41	35
1765	Identification of fusion genes in breast cancer by paired-end RNA-sequencing. 2011 , 12, R6	227
1764	Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. 2011 , 3, 63	9
1763	Epidemiology of lung cancer: smoking, secondhand smoke, and genetics. 2011 , 20, 605-18	51
1762	Hematopathology. 2011 ,	
1761	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. 2011 , 43, 964-968	242
1760	New targeted therapies for gastric cancer. 2011 , 20, 595-604	19
1759	The evolving war on cancer. 2011 , 145, 19-24	174
1758	Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. 2011 , 204, 113-21	45
1757	Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. 2011 , 204, 525-35	44
1756	Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. 2011 , 204, 45-52	73

1755	Next-generation sequencing applied to molecular diagnostics. 2011 , 11, 425-44	32
1754	[Non-small cell lung carcinoma: Perspectives for the twenty-first century?]. 2011 , 40, 368-70	0
1753	[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]. 2011 , 40, 371-8	5
1752	ALK-positive extramedullary plasmacytoma with expression of the CLTC-ALK fusion transcript. 2011 , 207, 587-91	25
1751	New driver mutations in non-small-cell lung cancer. 2011 , 12, 175-80	881
1750	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. 2011 , 12, 1004-12	732
1749	Hope without hype: EML4-ALK inhibition for treatment of lung cancer. 2011 , 12, 983-4	3
1748	Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. 2011 , 2, 379-384	27
1747	2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity. 2011 , 54, 6328-41	38
1746	Cancer broncho-pulmonaire chez le non-fumeur. 2011 , 163-194	
1745	Unraveling the genetics of cancer: genome sequencing and beyond. 2011 , 12, 407-30	73
1744	Personalized therapy for non-small cell lung cancer: hype or clinical reality?. 2011 , 23, 30-5	2
1743	Sex and gender differences in non-small cell lung cancer. 2011 , 23, 137-45	42
1742	Personalized therapy for non-small cell lung cancer: which drug for which patient?. 2011 , 23, 281-90	9
1741	Biomarkers and the genetics of early neoplastic lesions. 2010 , 9, 41-64	12
1740	Systemic Therapy for Lung Cancer for the Radiation Oncologist. 2011 , 247-266	
1739	Pathology of Lung Cancer. 2011 , 53-62	
1738	EML4 (echinoderm microtubule associated protein like 4). 2011 ,	

1737	ALK (anaplastic lymphoma receptor tyrosine kinase). 2011,	5
1736	Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy. 2011, 10, 1	2
1735	Histologic Features of ALK-Expressing Adenocarcinomas of the Lung. 2011, 10, 32	3
1734	Lung: non-small cell carcinoma with inv(2)(p21p23). 2011,	
1733	Clinicopathologic Implications of ALK Gene Copy Number Gain in Non-small Cell Lung Cancer. 2011, 10, 87	1
1732	Evaluation of ALK gene status in primary lung adenocarcinoma and matched metastases. 2011, 6, 1146	6
1731	Aberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilization. 2011, 6, e17854	3
1730	An evolutionary conserved role for anaplastic lymphoma kinase in behavioral responses to ethanol. 2011, 6, e22636	78
1729	Finding ALK-positive lung cancer: what are we really looking for?. 2011, 6, 411-3	27
1728	Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer. 2011, 6, 399-403	3
1727	Molecular Biology and Genetics of Lung Cancer. 2011, 3-15	2
1726	Comprehensive histologic analysis of ALK-rearranged lung carcinomas. 2011, 35, 1226-34	239
1725	Tumor genotyping for breast cancer: at the front door. 2011, 8, 383-385	
1724	Identification of RHOXF2 (PEPP2) as a cancer-promoting gene by expression cloning. 2012, 40, 93-8	8
1723	Novel therapeutic targets in non-small cell lung cancer. 2011, 6, 1601-12	110
1722	Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. 2011, 6, 459-65	232
1721	New discoveries in lung cancer biology: paving the road of personalized medicine. 2011, 8, 1-4	
1720	Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. 2011, 6, 1359-66	135

1719	What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. 2011 , 43, 103-15	46
1718	The techniques of endobronchial ultrasound-guided transbronchial needle aspiration. 2011 , 6, 57-64	14
1717	Ron kinase transphosphorylation sustains MET oncogene addiction. 2011 , 71, 1945-55	61
1716	miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. 2011 , 118, 6881-92	141
1715	Do complex mutations of the epidermal growth factor receptor gene reflect intratumoral heterogeneity?. 2011 , 6, 1144-6	3
1714	Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. 2011 , 6, 21-7	133
1713	Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. 2011 , 96, 464-7	77
1712	[Molecular targeted drugs against ALK fusions]. 2011 , 138, 3-7	
1711	An approach to personalized medicine: the BATTLE trial. 2011 , 1, 699-705	
1710	Personalized medicine in non-small-cell lung cancer: has it come of age?. 2011 , 1, 1601-1603	
1709	Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer. 2011 , 6, 1976-83	14
1708	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. 2011 , 6, 1474-80	131
1707	Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. 2011 , 6, 905-12	53
1706	A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. 2011 , 6, 1379-91	79
1705	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. 2011 , 6, 774-80	185
1704	Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. 2011 , 6, 1677-86	53
1703	[Recent progress for chemotherapy in advanced non-small cell lung cancer]. 2011 , 100, 763-71	
1702	[108th Scientific Meeting of the Japanese Society of Internal Medicine: panel discussion: 2. Discovery and clinical application of a novel oncogene in lung cancer]. 2011 , 100, 2569-73	

1701	Incorporation of crizotinib into the NCCN guidelines. 2011 , 9, 1328-30	16
1700	Therapeutische Strategien bei SCLC und NSCLC. 2011 , 14, 24-34	
1699	Crizotinib and testing for ALK. 2011 , 9, 1335-41	92
1698	Oncogenic mutations of ALK in neuroblastoma. 2011 , 102, 302-8	42
1697	Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer. 2011 , 102, 1602-4	9
1696	Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. 2011 , 78, 999-1005	113
1695	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. 2011 , 17, 304-12	77
1694	Cancer genomics: from discovery science to personalized medicine. 2011 , 17, 297-303	415
1693	Hunting ALK to feed targeted cancer therapy. 2011 , 17, 290-1	10
1692	Metabolism unhinged: IDH mutations in cancer. 2011 , 17, 291-3	123
1691	Advances in the preclinical testing of cancer therapeutic hypotheses. 2011 , 10, 179-87	100
1690	Towards systematic functional characterization of cancer genomes. 2011 , 12, 487-98	64
1689	The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. 2011 , 30, 2581-6	120
1688	Can cancer clinical trials be fixed?. 2011 , 29, 13-5	2
1687	Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. 2011 , 141, 476-80	35
1686	Personalized treatment of lung cancer. 2011 , 38, 274-83	33
1685	Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. 2011 , 38, 173-85	49
1684	Lung cancer: New biological insights and recent therapeutic advances. 2011 , 61, 91-112	329

1683	Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment. 2011 , 12, 360-8	22
1682	Protein kinase biochemistry and drug discovery. 2011 , 39, 192-210	93
1681	Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group. 2011 , 21, 7261-4	21
1680	CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. 2011 , 19, 679-90	477
1679	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. 2011 , 5, 413-24	21
1678	Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). 2011 , 54, 6342-63	645
1677	Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. 2011 , 1, 297-311	40
1676	EGFR mutations and lung cancer. 2011 , 6, 49-69	387
1675	Aberrant expression and mutation-inducing activity of AID in human lung cancer. 2011 , 18, 2084-92	32
1674	Polymerase reaction without primers throughout for the reconstruction of full-length cDNA from products of rapid amplification of cDNA ends (RACE). 2011 , 33, 1301-7	4
1673	High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. 2011 , 357, 363-71	36
1672	Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features. 2011 , 16, 287-93	78
1671	Lung cancers unrelated to smoking: characterized by single oncogene addiction?. 2011 , 16, 294-305	22
1670	[Tyrosine kinase inhibitors in oncology]. 2011 , 52, 595-600	2
1669	[Treatment of non-small cell lung cancer]. 2011 , 52, 1414-21	
1668	Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race. 2011 , 13, 774-9	3
1667	Targeted therapies in advanced non-small cell lung cancer: success or failure?. 2011 , 4, 23-26	1
1666	Mind-mapping for lung cancer: towards a personalized therapeutics approach. 2011 , 28, 173-94	15

1665 Medicatie bij longcarcinoom. **2011**, 54, 502-505

1664 Targetable "driver" mutations in non small cell lung cancer. **2011**, 2, 178-88

17

1663 Molecular oncology of lung cancer. **2011**, 59, 527-37

51

1662 Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. **2011**, 4, 16

96

1661 Genetically informed lung cancer medicine. **2011**, 223, 230-40

53

1660 PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. **2011**, 224, 564-74

27

1659 Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors. **2011**, 103, 574-86

18

1658 ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. **2011**, 50, 146-53

117

1657 Fusion gene microarray reveals cancer type-specificity among fusion genes. **2011**, 50, 348-57

13

1656 Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. **2011**, 6, 1680-92

18

1655 Virtual screening and further development of novel ALK inhibitors. **2011**, 19, 3086-95

10

1654 Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models. **2011**, 21, 463-6

31

1653 Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors. **2011**, 21, 3788-93

24

1652 Synthesis of an aryloxy oxo pyrimidinone library that displays ALK-selective inhibition. **2011**, 21, 4592-6

9

1651 [Chromosomal rearrangements and fusion genes in carcinoma]. **2011**, 98, 1395-401

1650 Genomic and Cellular Pathology of Lung Cancer. **2011**, 7, 313-322

1

1649 Crizotinib: an anaplastic lymphoma kinase inhibitor. **2011**, 7, 947-53

15

1648 Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. **2011**, 24, 430-42

168

1647	Con: the case for expanded lung cancer research support. 2011 , 184, 1234-6	0
1646	[Synthetic lethality as a new concept for the treatment of cancer]. 2011 , 136, 1526-30	1
1645	Transcriptional consequences of genomic structural aberrations in breast cancer. 2011 , 21, 676-87	67
1644	Lung cancer in never smokers. 2011 , 32, 10-21	26
1643	Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. 2011 , 18, 1613-28	30
1642	Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy. 2011 , 32, 78-93	8
1641	Targeted therapies for lung cancer: clinical experience and novel agents. 2011 , 17, 512-27	80
1640	EGFR mutant lung cancer. 2012 , 355, 59-81	5
1639	Emerging technologies for improved stratification of cancer patients: a review of opportunities, challenges, and tools. 2011 , 17, 451-64	4
1638	Reply to M.C. Garassino et al. 2011 , 29, 3838-3839	1
1637	Targeting anaplastic lymphoma kinase in lung cancer. 2011 , 17, 2081-6	230
1636	New strategies in non-small cell lung cancer: improving outcomes in chemoradiotherapy for locally advanced disease. 2011 , 17, 4192-9	15
1635	New strategies for treatment of ALK-rearranged non-small cell lung cancers. 2011 , 17, 7213-8	72
1634	Customizing systemic therapy in patients with advanced non-small cell lung cancer. 2011 , 3, 207-18	8
1633	Lung cancer in never smokers. 2011 , 7, 1195-211	30
1632	Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. 2011 , 3, 113-25	77
1631	Biology-driven phase II trials: what is the optimal model for molecular selection?. 2011 , 29, 1236-8	56
1630	Anaplastic lymphoma kinase in human cancer. 2011 , 47, R11-23	96

1629	Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer. 2011 , 17, 39-45	25
1628	Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. 2011 , 6, 466-72	243
1627	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. 2011 , 71, 6051-60	468
1626	Understanding the enemy. 2011 , 3, 98ps37	4
1625	A new frontier in personalized cancer therapy: mapping molecular changes. 2011 , 7, 873-94	12
1624	Making sense of cancer genomic data. 2011 , 25, 534-55	260
1623	Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. 2011 , 10, 1127-36	26
1622	Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. 2011 , 136, 228-38	33
1621	Neuroblastoma therapy: what is in the pipeline?. 2011 , 18, R213-31	24
1620	Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. 2011 , 71, 4403-11	168
1619	Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. 2011 , 17, 2140-8	109
1618	Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. 2011 , 17, 3341-8	82
1617	Targeting oncogenic ALK: a promising strategy for cancer treatment. 2011 , 10, 569-79	87
1616	Comparison of 2 cell-based phosphoprotein assays to support screening and development of an ALK inhibitor. 2011 , 16, 164-73	6
1615	Genetic and epigenetic changes in lung carcinoma and their clinical implications. 2011 , 24, 932-43	56
1614	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. 2011 , 6, 244-85	317 ⁸
1613	Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. 2011 , 3, 108ra114	175
1612	The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. 2011 , 1, 1119-1126	16

1611	Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!. 2011 , 23, 245-6	3
1610	A new BATTLE in the evolving war on cancer. 2011 , 1, 14-6	10
1609	ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. 2011 , 17, 7394-401	147
1608	Rare subtypes of adenocarcinoma of the lung. 2011 , 11, 1535-42	14
1607	Personalized management for non-small-cell lung cancer. 2011 , 58-67	
1606	ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. 2011 , 9, e1001156	44
1605	Forty years of translational cancer research. 2011 , 1, 383-90	9
1604	deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. 2011 , 7, e1001138	409
1603	Making a Difference with Teamwork. 2012 , 19, 5-6	78
1602	The importance of multidisciplinary team management of patients with non-small-cell lung cancer. 2012 , 19, S7-S15	38
1601	Drug resistance and its significance for treatment decisions in non-small-cell lung cancer. 2012 , 19, S45-51	49
1600	Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. 2012 , 19, S73-85	9
1599	Advancing personalized cancer medicine in lung cancer. 2012 , 136, 1210-6	6
1598	Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. 2012 , 23, 1223-1229	21
1597	Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. 2012 , 18, 4682-90	191
1596	Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript. 2012 , 28, 3232-9	108
1595	Oncogenic MAP2K1 mutations in human epithelial tumors. 2012 , 33, 956-61	28
1594	Molecular diagnostics of lung cancers at the Brigham and Women's Hospital and Dana-Farber Cancer Institute: technology in rapid evolution. 2012 , 136, 1198-200	7

1593	Going beyond EGFR. 2012 , 23 Suppl 10, x197-203	8
1592	Chapter 6: Structural variation and medical genomics. 2012 , 8, e1002821	24
1591	Treatment of ALK-positive non-small cell lung cancer. 2012 , 136, 1201-4	26
1590	Anaplastic lymphoma kinase () inhibitors for second-line therapy of non-small cell lung cancer. 2012 , 3, 91-99	2
1589	The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. 2012 , 19, S24-32	25
1588	Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives. 2012 , 13, 16554-79	9
1587	Personalized medicine and treatment approaches in non-small-cell lung carcinoma. 2012 , 5, 113-23	16
1586	Ancillary testing in lung cancer diagnosis. 2012 , 2012, 249082	13
1585	Personalized targeted therapy for lung cancer. 2012 , 13, 11471-96	45
1584	Rare cancer trial design: lessons from FDA approvals. 2012 , 18, 5172-8	38
1583	Targeted therapy for brain metastases. 2012 , 65, 109-42	11
1582	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. 2012 , 18, 1472-82	865
1581	Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. 2012 , 7, 1315-26	135
1580	Detection of ALK fusion in lung cancer using fluorescence in situ hybridization. 2012 , 20, 426-31	8
1579	Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. 2012 , 23, 2931-2936	32
1578	IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma: novel concepts and radiologic implications. 2012 , 27, 340-53	48
1577	Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma. 2012 , 17, 62-68	1
1576	Microtubule-Associated Protein-Like 4 Anaplastic Lymphoma Kinase Rearrangement in Lung Adenocarcinoma. 2012 , 17, 202-206	

1575	Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. 2012 , 72, 100-11	512
1574	Personalized therapy of lung cancer. 2012 , 35 Suppl 1, 14-9	5
1573	ChiTaRS: a database of human, mouse and fruit fly chimeric transcripts and RNA-sequencing data. 2013 , 41, D142-51	39
1572	Cancer genes in lung cancer: racial disparities: are there any?. 2012 , 3, 467-80	92
1571	Therapeutic Kinase Inhibitors. 2012 ,	1
1570	Worldwide overview of the current status of lung cancer diagnosis and treatment. 2012 , 136, 1478-81	47
1569	Pitfalls in lung cancer molecular pathology: how to limit them in routine practice?. 2012 , 19, 2638-51	17
1568	Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. 2012 , 19, 3689-700	10
1567	Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. 2012 , 18, 3592-602	93
1566	Targeted therapy for squamous cell lung cancer. 2012 , 1, 293-300	30
1565	Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. 2012 , 4, 141ra91	119
1564	Synthetische Letalit als Therapiekonzept f die Behandlung maligner Neoplasien. 2012 , 33, 284-289	
1563	Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. 2012 , 265, 939-48	89
1562	Molecular logic underlying chromosomal translocations, random or non-random?. 2012 , 113, 241-79	15
1561	A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. 2012 , 18, 5682-9	109
1560	First-line therapy of mutated non-small cell lung cancer: an update. 2012 , 35, 293-9	1
1559	Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. 2012 , 18, 6373-83	391
1558	Lipoprotein lipase is frequently overexpressed or translocated in cervical squamous cell carcinoma and promotes invasiveness through the non-catalytic C terminus. 2012 , 107, 739-47	9

1557	Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. 2012 , 3, e449	25
1556	Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. 2012 , 25, 1473-80	103
1555	Strategies against Xalkori resistance. 2012 , 5, 167-167	
1554	Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies. 2012 , 2, e65	18
1553	Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. 2012 , 31, 4667-76	36
1552	Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. 2012 , 31, 4859-67	47
1551	Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells. 2012 , 106, 763-7	38
1550	New developments in the treatment of ALK-driven malignancies. 2012 , 2, 835-852	1
1549	Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. 2012 , 18, 2443-51	205
1548	Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. 2012 , 18, 6219-26	123
1547	Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?. 2012 , 13, 1376-83	81
1546	Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. 2012 , 18, 6599-608	151
1545	CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. 2012 , 11, 670-9	60
1544	More than just an oncogene translocation and a kinase inhibitor: Kevin's story. 2012 , 30, 110-2	4
1543	A framework for identification of actionable cancer genome dependencies in small cell lung cancer. 2012 , 109, 17034-9	138
1542	Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. 2012 , 2, 798-811	323
1541	The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. 2012 , 16 Suppl 2, S45-54	16
1540	Analysis of the Growth Control Network Specific for Human Lung Adenocarcinoma Cells. 2012 , 7, 337-368	1

1539	MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. 2012 , 72, 3048-59	43
1538	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. 2012 , 4, 120ra17	948
1537	Therapeutic advances in non-small cell lung cancer. 2012 , 67, 1097-101	20
1536	Evaluating translocation gene fusions by SNP array data. 2012 , 11, 15-27	5
1535	Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents. 2012 , 2012, 478607	
1534	ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. 2012 , 2, 41	33
1533	NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases. 2012 , 2012, 123253	22
1532	Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. 2012 , 2012, 729532	17
1531	Genetic and biochemical alterations in non-small cell lung cancer. 2012 , 2012, 940405	34
1530	The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. 2012 , 18, 4725-32	68
1529	Interplay between menin and K-Ras in regulating lung adenocarcinoma. 2012 , 287, 40003-11	30
1528	ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. 2012 , 25, 1516-25	101
1527	Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. 2012 , 4, 120ps2	83
1526	Morphologic features of carcinomas with recurrent gene fusions. 2012 , 19, 417-24	6
1525	Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase. 2012 , 139, 2523-34	16
1524	Tobacco, inflammation, and respiratory tract cancer. 2012 , 18, 3901-38	46
1523	FGFR1 amplification in squamous cell carcinoma of the lung. 2012 , 7, 1775-1780	147
1522	A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK. 2012 , 7, 1198-9	26

1521	The role of molecular diagnostics in cancer diagnosis and treatment. 2012 , 35 Suppl 1, 8-12	6
1520	Molecular characterization by immunocytochemistry of lung adenocarcinoma on cytology specimens. 2012 , 56, 603-10	19
1519	DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients. 2012 , 4, 33-37	12
1518	A phase I study of concurrent external beam radiotherapy with weekly topotecan for primary treatment of locally advanced lung cancers. 2012 , 7, e44-e45	
1517	Oncogenic fusions involving exon 19 of ALK. 2012 , 7, e44	3
1516	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. 2012 , 7, 348-54	170
1515	Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. 2012 , 7, e14-6	107
1514	Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. 2012 , 142, 1020-1026	43
1513	Are anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer prognostic, predictive, or both?. 2012 , 7, 5-7	4
1512	Recent advances in lung cancer: summary of presentations from the 47 th annual meeting of the American Society of Clinical Oncology (ASCO) 2011. 2012 , 7, 260-5	3
1511	Oncogenic Fusions Involving Exon 19 of ALK. 2012 , 7, e44	1
1510	Challenges in the codevelopment of companion diagnostics. 2012 , 9, 485-496	9
1509	Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements. 2012 , 2, 895-907	1
1508	Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. 2012 , 7, 85-9	71
1507	Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. 2012 , 7, 90-7	108
1506	[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 3) Non-small cell lung cancer]. 2012 , 101, 2520-5	1
1505	A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. 2012 , 28, 1225-30	4
1504	A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis. 2012 , 5, 95-106	56

1503	A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer. 2012 , 7, 913-8	14
1502	Gene fusions in non-small-cell lung cancer. 2012 , 1, 283-292	1
1501	KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. 2012 , 28, 1187-92	45
1500	EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. 2012 , 7, 98-104	76
1499	First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component. 2012 , 7, e39-e41	40
1498	Anti-MET-targeted therapy for NSCLC: has it come of age?. 2012 , 2, 1053-1056	
1497	Genetic changes in squamous cell lung cancer: a review. 2012 , 7, 924-33	98
1496	Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. 2012 , 72, 3312-23	95
1495	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. 2012 , 13, 1011-9	983
1494	Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. 2012 , 17, 1351-75	175
1493	Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. 2012 , 18, 3737-42	64
1492	Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. 2012 , 25, 819-31	40
1491	Impact of age on epidermal growth factor receptor mutation in lung cancer. 2012 , 78, 207-11	32
1490	The role of molecular analyses in the era of personalized therapy for advanced NSCLC. 2012 , 76, 131-7	26
1489	Anaplastic lymphoma kinase as a therapeutic target. 2012 , 16, 1127-38	23
1488	The paradigm of personalized therapy in oncology. 2012 , 16 Suppl 1, S7-16	16
1487	RET fusion genes in non-small-cell lung cancer. 2012 , 30, 4439-41	31
1486	RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. 2012 , 30, 4352-9	376

1485	A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. 2012 , 18, 5606-16	54
1484	Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. 2012 , 61, 1017-25	79
1483	Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. 2012 , 52, 549-73	82
1482	Advances in treatment of lung cancer with targeted therapy. 2012 , 136, 504-9	57
1481	PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. 2012 , 18, 1699-704	85
1480	Lung cancer genotype-based therapy and predictive biomarkers: present and future. 2012 , 136, 1482-91	33
1479	A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors. 2012 , 7, 1968-74	12
1478	The complexity of prostate cancer: genomic alterations and heterogeneity. 2012 , 9, 652-64	138
1477	Lung Cancer Therapy Annual 7. 2012 ,	0
1476	Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. 2012 , 77, 319-25	89
1475	Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. 2012 , 77, 288-92	102
1474	Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. 2012 , 23, 1738-43	42
1473	Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. 2012 , 136, 796-803	98
1472	The transcriptional landscape and mutational profile of lung adenocarcinoma. 2012 , 22, 2109-19	435
1471	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. 2012 , 11, 485-91	166
1470	Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. 2012 , 83, e453-64	31
1469	EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. 2012 , 461, 245-57	168
1468	Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts. 2012 , 131, 1453-1466	21

1467	Actualité en pathologie moléculaire dans les cancers du poumon non à petites cellules. 2012 , 14, 530-537	
1466	Directed Therapies in Lung Cancer: New Hope?. 2012 , 48, 367-371	1
1465	Directed therapies in lung cancer: new hope?. 2012 , 48, 367-71	5
1464	Cancer vulnerabilities unveiled by genomic loss. 2012 , 150, 842-54	163
1463	Characterising Somatic Mutations in Cancer Genome by Means of Next-generation Sequencing. 2012 ,	
1462	Molecular Pathology of Non-Small Cell Lung Cancer. 2012 , 5, 903-18	2
1461	Molecular markers for incidence, prognosis, and response to therapy. 2012 , 21, 161-75	6
1460	Personalizing medicine: strategies for implementing the evaluation of anaplastic lymphoma kinase rearrangement in non-small-cell lung cancer in Portugal. 2012 , 18, 244-6	6
1459	Translocation EML4-ALK : Techniques de détection, variantes, implications thérapeutiques. 2012 , 4, 599-603	
1458	[Cavitating nodules in a 40-year-old non-smoking woman: a very particular tumour]. 2012 , 29, 916-9	3
1457	Saudi Lung Cancer Guidelines Supplement 2012. Introduction from the Guest Editor. 2012 , 5 Suppl 1, S2-3	
1456	Drug repositioning for personalized medicine. 2012 , 4, 27	144
1455	Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma. 2012 , 57, 682-4	16
1454	Vandetanib for the treatment of lung cancer. 2012 , 21, 1211-21	5
1453	Targeted therapy of non-small-cell lung carcinoma. 2012 , 6, 41-56	3
1452	Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors. 2012 , 22, 1153-9	40
1451	Translating genomic information into clinical medicine: lung cancer as a paradigm. 2012 , 22, 2101-8	64
1450	Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1.1]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles. 2012 , 55, 449-64	33

1449	Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy. 2012 , 185, 606-11	66
1448	Targeted therapy for NSCLC: ALK inhibition. 2012 , 18, 271-4	6
1447	Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. 2012 , 106, 173-83	52
1446	Impact of genomics on personalized cancer medicine. 2012 , 18, 612-8	44
1445	Cancer biomarkers: selecting the right drug for the right patient. 2012 , 11, 201-14	202
1444	Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. 2012 , 166, 1669-83	72
1443	What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?. 2012 , 23 Suppl 8, viii28-34	35
1442	Molecular-targeted therapies for ovarian cancer: prospects for the future. 2012 , 17, 424-9	25
1441	Mechanisms and impacts of chromosomal translocations in cancers. 2012 , 6, 263-74	15
1440	Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. 2012 , 18, 4570-9	326
1439	Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. 2012 , 18, 4449-57	233
1438	What are we learning from the cancer genome?. 2012 , 9, 621-30	43
1437	Genomic landscape of non-small cell lung cancer in smokers and never-smokers. 2012 , 150, 1121-34	860
1436	Lung Cancer. 2012 , 776-787	
1435	Lung Cancer: Treatment. 2012 , 801-809	
1434	A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. 2012 , 18, 521-8	433
1433	Diagnosing the decline in pharmaceutical R&D efficiency. 2012 , 11, 191-200	1152
1432	ROS1 rearrangements define a unique molecular class of lung cancers. 2012 , 30, 863-70	1170

1431	Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. 2012 , 22, 928-31	63
1430	Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. 2012 , 12, 593-602	70
1429	MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. 2012 , 180, 1772-80	42
1428	A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK. 2012 , 423, 319-24	52
1427	Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). 2012 , 38, 173-84	26
1426	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. 2012 , 38, 416-30	97
1425	ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. 2012 , 48, 961-73	71
1424	Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. 2012 , 22, 45-9	36
1423	Crizotinib in the treatment of non-small-cell lung cancer. 2012 , 13, 1195-201	60
1422	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 2012 , 44, 1104-10	919
1421	Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. 2012 , 13, 719	28
1420	A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. 2012 , 12, 558	33
1419	Molecular pathology of non-small cell lung cancer: a practical guide. 2012 , 138, 332-46	95
1418	Neuroblastoma: the impact of biology and cooperation leading to personalized treatments. 2012 , 49, 85-115	32
1417	KIF5B-RET fusions in lung adenocarcinoma. 2012 , 18, 375-7	636
1416	Treatment of lung cancer. 2012 , 50, 961-74	62
1415	Cancer treatment according to BRCA1 and BRCA2 mutations. 2012 , 9, 520-8	56
1414	ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. 2012 , 8, 646-54	57

1413	RET, ROS1 and ALK fusions in lung cancer. 2012 , 18, 378-81	990
1412	The Role of Midkine in Neural Development and Patterning. 2012 , 15-28	
1411	EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. 2012 , 83, 248-56	36
1410	Crizotinib: in locally advanced or metastatic non-small cell lung cancer. 2012 , 72, 99-107	32
1409	Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. 2012 , 12, 277-86	29
1408	Functional drug-gene interactions in lung cancer. 2012 , 12, 291-302	5
1407	Genetic insight and therapeutic targets in squamous-cell lung cancer. 2012 , 31, 4811-4	24
1406	Technological Advances in the Detection of Novel Fusion Genes. 2012 ,	1
1405	Crizotinib in ALK-positive lung cancer. 2012 , 13, 962-3	4
1404	Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and inpatient tumor heterogeneity. 2012 , 13, 321-5	20
1403	Anaplastic large cell lymphoma, ALK-positive. 2012 , 83, 293-302	78
1402	Structural mutations in cancer: mechanistic and functional insights. 2012 , 28, 550-9	54
1401	Recomendaciones para la determinaci3n de biomarcadores en el carcinoma de pulm3n no microc3nico avanzado. Consenso nacional de la Sociedad Espa3a de Anatom3 Patol3gica y de la Sociedad Espa3a de Oncolog3 M3dica. 2012 , 45, 14-28	6
1400	Personalizing medicine 3strategies for implementing the evaluation of ALK rearrangement in non-small-cell lung cancer in Portugal. 2012 , 18, 244-246	3
1399	ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. 2012 , 75, 66-72	25
1398	ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. 2012 , 75, 300-5	38
1397	Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. 2012 , 76, 26-31	36
1396	Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. 2012 , 76, 309-15	51

1395	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. 2012 , 76, 403-9	130
1394	Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung. 2012 , 76, 423-30	31
1393	Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy. 2012 , 77, 293-8	20
1392	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. 2012 , 77, 460-3	71
1391	Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. 2012 , 78, 100-6	67
1390	Discovery of small molecule cancer drugs: successes, challenges and opportunities. 2012 , 6, 155-76	363
1389	The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy. 2012 , 6, 204-10	15
1388	Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. 2012 , 19, S33-44	38
1387	Anaplastic Lymphoma Kinase Inhibitors for the Treatment of ALK-Positive Cancers. 2012 , 47, 281-293	10
1386	Treating ALK-positive lung cancer--early successes and future challenges. 2012 , 9, 268-77	195
1385	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. 2012 , 7, 199-210	25
1384	Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. 2012 , 29, 1599-605	3
1383	Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors. 2012 , 5, 302-308	
1382	Long-range transcriptome sequencing reveals cancer cell growth regulatory chimeric mRNA. 2012 , 14, 1087-96	16
1381	Cancéologie. 2012 , 4, 740-745	
1380	The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma. 2012 , 14, 1075-86	13
1379	Les biomarqueurs à rechercher en 2012 et dans le futur proche dans les cancers bronchiques non à petites cellules (CBNPC). 2012 , 4, 578-582	
1378	Molecular Diagnosis of Lung Cancer. 2012 , 87-97	

1377	Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. 2012 , 12, 151-62	17
1376	Molecular Genetics and Personalized Medicine. 2012 ,	1
1375	[Translational research and diagnostics in lung cancer]. 2012 , 33 Suppl 2, 269-72	2
1374	The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase. 2012 , 287, 37447-57	33
1373	A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. 2012 , 22, 436-45	367
1372	Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review. 2012 , 16, 143-50	31
1371	Comprehensive genomic characterization of squamous cell lung cancers. <i>Nature</i> , 2012 , 489, 519-25	50.4 2820
1370	Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. 2012 , 18, 382-4	664
1369	Serous Effusions. 2012 ,	6
1368	Novel treatment avenues for peripheral T-cell lymphomas. 2012 , 7, 1149-63	4
1367	Computational molecular docking studies on anticancer drugs. 2012 , 2, S734-S738	11
1366	Molecular Pathology of Lung Cancer. 2012 ,	5
1365	Gene Fusion Markup Language: a prototype for exchanging gene fusion data. 2012 , 13, 269	1
1364	Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. 2012 , 12, 612	34
1363	Personalizing lung cancer prevention through a reverse migration strategy. 2013 , 329, 221-40	4
1362	Tyrosine kinase inhibitors in lung cancer. 2012 , 26, 589-605, viii	24
1361	KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. 2012 , 7, e31323	198
1360	A novel classification of lung cancer into molecular subtypes. 2012 , 7, e31906	82

1359	Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. 2012 , 7, e42264	35
1358	Next-generation cDNA screening for oncogene and resistance phenotypes. 2012 , 7, e49201	8
1357	EML4-ALK fusion gene in Korean non-small cell lung cancer. 2012 , 27, 228-30	16
1356	EML4-ALK-Positive Non-Small Cell Lung Cancer in a Patient Treated with Azathioprine for Ulcerative Colitis. 2012 , 98, e98-e101	2
1355	Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer. 2012 , 2012, 957437	20
1354	[Management of crizotinib, a new individualized treatment]. 2012 , 99, 787-91	2
1353	Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks. 2012 , 2012, 373506	11
1352	Molecular Pathogenesis of Non-Small Cell Lung Carcinomas. 2012 , 11, 12	4
1351	Non-small cell lung cancer: the era of targeted therapy. 2012 , 3, 31-41	6
1350	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. 2012 , 2, 35-49	6
1349	ALK Inhibitors, a Pharmaceutical Perspective. 2012 , 2, 17	17
1348	A Screening Method for the ALK Fusion Gene in NSCLC. 2012 , 2, 24	59
1347	The Role of Tyrosine Kinases in the Pathogenesis and Treatment of Lung Disease. 2012 ,	2
1346	The Role of Histology and Molecular Markers in NSCLE. 2012 , 27, 38-40	
1345	Activating Mutations and Targeted Therapy in Cancer. 2012 ,	3
1344	Pancoast Tumors: Surgical Approaches and Techniques. 2012 ,	0
1343	Targeted therapy in sarcoma: should we be lumpers or splitters?. 2012 , 652-7	2
1342	Chemotherapy-induced nausea and vomiting incidence and prevalence. 2012 , 541-3	7

1341	Assessing the clinical significance of tumor markers in common neoplasms. 2012 , 4, 2558-78	8
1340	Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population. 2012 , 67, 845-7	15
1339	MET targeted therapy for lung cancer: clinical development and future directions. 2012 , 3, 53-67	4
1338	Crizotinib in the treatment of non-small-cell lung carcinoma. 2012 , 16, 480-4	3
1337	Molecular pathology of lung cancer: key to personalized medicine. 2012 , 25, 347-69	171
1336	Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer. 2012 , 72, 1921-8	71
1335	Translating cancer 'omics' to improved outcomes. 2012 , 22, 188-95	84
1334	ALKoma: a cancer subtype with a shared target. 2012 , 2, 495-502	141
1333	Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit. 2012 , 9, 283-92	16
1332	Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. 2012 , 227, 446-55	72
1331	Respiratory cytology in the era of molecular diagnostics: a review. 2012 , 40, 556-63	7
1330	Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. 2012 , 51, 925-32	20
1329	A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance. 2012 , 131, 970-9	7
1328	RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer. 2012 , 1, 68-75	38
1327	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. 2012 , 118, 3579-86	41
1326	Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. 2012 , 118, 4427-36	98
1325	Lung cancer with translocation in the anaplastic lymphoma kinase gene: a disease within a disease. 2012 , 118, 4370-1	
1324	Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. 2012 , 118, 4502-11	202

1323	Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. 2012 , 118, 4486-94	74
1322	Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. 2012 , 118, 5302-9	68
1321	Hypogonadism related to crizotinib therapy: implications for patient care. 2012 , 118, E1-2	7
1320	Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. 2012 , 118, 5840-7	44
1319	Inhibitors of the anaplastic lymphoma kinase. 2012 , 21, 985-94	46
1318	Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. 2012 , 30, 433-46	47
1317	Sequence analysis of mutations and translocations across breast cancer subtypes. <i>Nature</i> , 2012 , 486, 405-9	50.4 895
1316	Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia. 2012 , 25, 795-804	72
1315	Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. 2012 , 340, 549-57	59
1314	Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors. 2012 , 55, 115-25	25
1313	Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. 2012 , 25, 1462-72	83
1312	Novel mechanism of conjoined gene formation in the human genome. 2012 , 12, 45-61	19
1311	The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. 2012 , 55, 6523-40	35
1310	Driver mutations as predictive biomarkers in lung cancer. 2012 , 1, 21-29	
1309	Exploring the cancer genome in the era of next-generation sequencing. 2012 , 6, 48-55	20
1308	The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation. 2012 , 14, 105-10	32
1307	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). 2012 , 14, 338-49	29
1306	[Non-small cell lung cancer. Subtyping and predictive molecular marker investigations in cytology]. 2012 , 33, 301-7	6

1305	ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment. 2012 , 190, 381-8	7
1304	Les biomarqueurs émergents dans le cancer bronchique non à petites cellules. 2012 , 14, 316-319	
1303	Pulmonary adenocarcinoma: a renewed entity in 2011. 2012 , 17, 50-65	56
1302	High-throughput resequencing of target-captured cDNA in cancer cells. 2012 , 103, 131-5	14
1301	ALK status in a primary lung tumour and metachronous metastases. 2012 , 60, 843-5	3
1300	Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. 2012 , 60, 187-98	49
1299	How chemoproteomics can enable drug discovery and development. 2012 , 19, 11-22	116
1298	Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). 2012 , 13, 252-66	95
1297	Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges. 2012 , 83, 130-44	22
1296	Interrogating genomic and epigenomic data to understand prostate cancer. 2012 , 1825, 186-96	12
1295	Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). 2012 , 20, 1271-80	131
1294	Les nouveautés dans les carcinomes broncho-pulmonaires non à petites cellules. 2012 , 2012, 47-54	
1293	EBUS and EUS guided fine needle aspirations for molecular diagnostic analysis in lung cancer. 2012 , 3, 201-206	3
1292	Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: a novel ALK fusion gene?. 2012 , 103, 390-2	5
1291	Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. 2012 , 103, 1189-94	55
1290	Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects. 2012 , 103, 1391-6	12
1289	Midkine in the pathology of cancer, neural disease, and inflammation. 2012 , 62, 445-55	39
1288	Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. 2012 , 51, 127-39	215

1287	Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. 2012 , 51, 590-7	67
1286	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. 2012 , 118, 729-39	114
1285	Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer. 2012 , 130, 1777-86	23
1284	Prädiktive Biomarker als Entscheidungsgrundlage für die onkologische Therapie. 2012 , 27, 27-32	0
1283	Personalized cancer medicine and the future of pathology. 2012 , 460, 3-8	28
1282	The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. 2012 , 131, 365-72	41
1281	Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants. 2013 , 52, 79-83	7
1280	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. 2013 , 119, 356-62	122
1279	Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer. 2013 , 32, 29	11
1278	SOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data. 2013 , 14, R12	147
1277	Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC). 2013 , 2, 1-9	2
1276	Tailored management of advanced squamous non-small cell lung cancer (NSCLC). 2013 , 2, 10-16	
1275	Advanced non-squamous non-small-cell lung cancer: who and when should be biologically screened today? Tomorrow?. 2013 , 2, 17-21	1
1274	Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis. 2013 , 7, 157-71	24
1273	Cancer Genomics. 2013 ,	4
1272	The impact of genomic changes on treatment of lung cancer. 2013 , 188, 770-5	76
1271	Inhaled gene therapy in lung cancer: proof-of-concept for nano-oncology and nanobiotechnology in the management of lung cancer. 2013 , 9, 1171-94	16
1270	LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. 2013 , 56, 5673-4	41

1269	Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs. 2013 , 1, 67-76	
1268	Fibroblast-mediated drug resistance in cancer. 2013 , 85, 1033-41	105
1267	FUSIM: a software tool for simulating fusion transcripts. 2013 , 14, 13	14
1266	Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. 2013 , 14, 505	25
1265	Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. 2013 , 13, 262	39
1264	Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes. 2013 , 13, 8	4
1263	A case of synchronous bilateral lung cancers: EML4-ALK positive adenocarcinoma in the right lung and adenocarcinoma in situ (the former bronchioloalveolar carcinoma) in the left lung. 2013 , 13, 25	2
1262	T-Cell Lymphomas. 2013 ,	1
1261	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. 2013 , 14, 472-80	510
1260	Impact of genetic targets on cancer therapy. Forward. 2013 , 779, v-vi	1
1259	Anaplastic lymphoma kinase status in rhabdomyosarcomas. 2013 , 26, 772-81	32
1258	Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. 2013 , 7 Suppl 1, S12-9	129
1257	[Viennese Clinical Weekly Review]. 2013 , 125, 228-9	
1256	Diagnostic Pathology of Pleuropulmonary Neoplasia. 2013 ,	3
1255	Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. 2013 , 15, 354-66	40
1254	Journey of the ALK-inhibitor CH5424802 to phase II clinical trial. 2013 , 36, 1051-4	16
1253	Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7. 2013 , 20, 3377-83	41
1252	Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer. 2013 , 133, 898-907	24

1251	Next Generation Sequencing in Cancer Research. 2013 ,	4
1250	Genotoxicity and carcinogenicity risk of carbon nanotubes. 2013 , 65, 2098-110	85
1249	Management of non-small-cell lung cancer: recent developments. 2013 , 382, 709-19	563
1248	Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). 2013 , 8, 27-33	82
1247	ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. 2013 , 8, 55-67	66
1246	Anti-vascular endothelial growth factor therapy in the era of personalized medicine. 2013 , 72, 1-12	16
1245	[Novel morphological and molecular aspects of lung cancer]. 2013 , 34, 419-28	7
1244	[Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing]. 2013 , 34, 310-7	5
1243	New Advances in the Precision Medicine of Lung Cancer. 2013 , 1, 1-8	3
1242	Using Cytogenetic Rearrangements for Cancer Prognosis and Treatment (Pharmacogenetics). 2013 , 1, 99-112	5
1241	Lung cancer in never smokers: disease characteristics and risk factors. 2013 , 88, 494-503	91
1240	Oncogenic driver mutations in lung cancer. 2013 , 1, 6	40
1239	The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. 2013 , 8, 1165-79	26
1238	Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches. 2013 , 53, 2376-89	75
1237	Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. 2013 , 119, 1467-77	59
1236	Optimization of energy transfer between quantum dots and gold nanoparticles in head-to-head configuration for detection of fusion gene. 2013 , 188, 729-734	6
1235	Targeted therapy and new anticancer drugs in advanced disease. 2013 , 23, 411-9	7
1234	Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. 2013 , 6, 405-12	10

1233 ADVANCES IN PERSONALIZED MEDICINE. **2013**, 471-494

1232 Echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement in congenital pulmonary airway malformation. **2013**, 14, 457-60 10

1231 Biologic approaches to drug selection and targeted therapy: hype or clinical reality?. **2013**, 23, 421-8 3

1230 ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. **2013**, 15, 341-6 94

1229 Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. **2013**, 436, 319-24 219

1228 Targeted therapy for NSCLC with driver mutations. **2013**, 13, 1401-12 33

1227 Management strategy of pulmonary nodule in 2013. **2013**, 94, 1081-94 32

1226 Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. **2014**, 95, 15-23 66

1225 Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. **2013**, 7, 1093-102 86

1224 Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. **2013**, 26, 1545-53 119

1223 Tyrosine kinase gene rearrangements in epithelial malignancies. **2013**, 13, 772-87 217

1222 Crizotinib in the treatment of non-small-cell lung cancer. **2013**, 14, 473-80 32

1221 Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. **2013**, 8, 1381-97 6

1220 Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. **2013**, 19, 1469-1472 420

1219 Genetic alterations defining NSCLC subtypes and their therapeutic implications. **2013**, 82, 179-89 189

1218 Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. **2013**, 24, 2080-7 92

1217 A genomics-based classification of human lung tumors. **2013**, 5, 209ra153 302

1216 Cancer genome landscapes. **2013**, 339, 1546-58 5058

1215	Identification of targetable FGFR gene fusions in diverse cancers. 2013 , 3, 636-47	511
1214	Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. 2013 , 66, 839-46	23
1213	Micro and Nano Flow Systems for Bioanalysis. 2013 ,	2
1212	Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. 2013 , 73, 5195-205	136
1211	Detectable clonal mosaicism in the human genome. 2013 , 50, 348-59	26
1210	ALK gene amplification is associated with poor prognosis in colorectal carcinoma. 2013 , 109, 2735-43	28
1209	ROS1 fusions in Chinese patients with non-small-cell lung cancer. 2013 , 24, 1822-1827	65
1208	Detection of structural DNA variation from next generation sequencing data: a review of informatic approaches. 2013 , 206, 432-40	96
1207	Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. 2013 , 1, 251-61	57
1206	KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. 2013 , 81, 377-381	7
1205	Lung Cancer Imaging. 2013 ,	1
1204	Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine. 2013 , 14, 609-26	14
1203	Strategies for improving outcomes in NSCLC: a look to the future. 2013 , 82, 375-82	26
1202	Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). 2013 , 31, 3004-11	243
1201	Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. 2013 , 155, 552-66	129
1200	Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. 2013 , 24, 2589-2593	101
1199	Bioinformatics for Diagnosis, Prognosis and Treatment of Complex Diseases. 2013 ,	
1198	HER2 and lung cancer. 2013 , 13, 1219-28	50

1197	Characteristics of lung cancers harboring NRAS mutations. 2013 , 19, 2584-91	100
1196	The Cancer Genome Atlas Pan-Cancer analysis project. 2013 , 45, 1113-20	3933
1195	The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma. 2013 , 121, 489-99	61
1194	ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer. 2013 , 24, 356-64	39
1193	Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma. 2013 , 82, 51-4	35
1192	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. 2013 , 19, 4273-81	411
1191	Genomische Analytik kleinzelliger Lungenkarzinome [neue Möglichkeiten in der Therapie?]. 2013 , 19, 958-961	
1190	Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. 2013 , 2, 409	19
1189	Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma. 2013 , 13, 471	9
1188	Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. 2013 , 6, 489	35
1187	Identification of gene fusions from human lung cancer mass spectrometry data. 2013 , 14 Suppl 8, S5	21
1186	Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. 2013 , 14, 818	56
1185	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. 2013 , 13, 685-700	409
1184	Fusion genes and their discovery using high throughput sequencing. 2013 , 340, 192-200	39
1183	Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. 2013 , 9, 377-86	17
1182	Case History: Xalkori (Crizotinib), a Potent and Selective Dual Inhibitor of Mesenchymal Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) for Cancer Treatment. 2013 , 48, 421-434	17
1181	Lung cancer biomarkers: present status and future developments. 2013 , 137, 1191-8	73
1180	Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?. 2013 , 13, 407-20	14

1179	Molecular Pathology of Lung Cancer. 2013 , 443-459	
1178	Deep sequencing in cancer research. 2013 , 43, 110-5	16
1177	Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. 2013 , 15, 51-61	57
1176	Impact of genetic markers on treatment of non-small cell lung cancer. 2013 , 779, 145-64	6
1175	Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. 2013 , 24, 59-66	82
1174	Identifying molecular drivers of gastric cancer through next-generation sequencing. 2013 , 340, 241-6	33
1173	Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. 2013 , 79, 40-5	27
1172	ALK in lung cancer: past, present, and future. 2013 , 31, 1105-11	319
1171	New targetable oncogenes in non-small-cell lung cancer. 2013 , 31, 1097-104	249
1170	MET as a possible target for non-small-cell lung cancer. 2013 , 31, 1089-96	152
1169	KRAS mutation: should we test for it, and does it matter?. 2013 , 31, 1112-21	194
1168	KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. 2013 , 119, 1486-94	44
1167	100 Years of cancer research in Japan. 2013 , 132, 1235-9	
1166	Clinical testing for molecular targets for personalized treatment in lung cancer. 2013 , 18, 233-7	3
1165	Molecular profile of lung cancer in never smokers. 2013 , 11, 248-53	19
1164	Mutation de l'EGFR, de l'Étude du gène [la pratique clinique : exemplarité ou exception ?]. 2013 , 5, 519-537	
1163	New guideline sets the ground rules for routine molecular testing in non-small cell lung cancer. 2013 , 15, 413-4	
1162	Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. 2013 , 59, 392-5	17

1161	Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. 2013 , 206, 330-9	15
1160	CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes. 2013 , 44, 1382-90	4
1159	Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma. 2013 , 80, 289-92	16
1158	ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. 2013 , 206, 357-73	43
1157	A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. 2013 , 81, 416-421	15
1156	Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. 2013 , 14, 636-43	22
1155	An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. 2013 , 81, 487-490	31
1154	EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report. 2013 , 81, 297-301	9
1153	A selective ALK inhibitor in ALK-rearranged patients. 2013 , 14, 564-5	6
1152	Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. 2013 , 31, 3987-96	260
1151	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. 2013 , 14, 1765-77	31
1150	Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. 2013 , 66, 870-4	31
1149	Crizotinib. 2013 , 71-90	
1148	Discovery of Predictive Biomarkers for Anticancer Drugs. 2013 , 21-70	
1147	Expression of anaplastic lymphoma kinase in Merkel cell carcinomas. 2013 , 44, 1656-64	17
1146	Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. 2013 , 79, 242-7	51
1145	Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. 2013 , 81, 328-336	45
1144	Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status. 2013 , 51, 46-8	10

1143	Treatment and detection of ALK-rearranged NSCLC. 2013 , 81, 145-54	27
1142	Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. 2013 , 81, 435-439	28
1141	[About new treatments in thoracic oncology]. 2013 , 69, 63-4	
1140	Prise en charge du nodule pulmonaire en 2013. 2013 , 94, 1084-1098	
1139	The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. 2013 , 30, 298-312	10
1138	The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice. 2013 , 24, 1094-103	36
1137	A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. 2013 , 80, 339-40	16
1136	Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib. 2013 , 81, 294-6	30
1135	[Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer]. 2013 , 69, 111-6	
1134	The first case of lung carcinosarcoma harboring in-frame deletions at exon19 in the EGFR gene. 2013 , 81, 491-494	8
1133	Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK. 2013 , 81, 175-84	2
1132	Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases. 2013 , 62, 305-14	30
1131	Lung Cancer. 2013 , 691-706	
1130	Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. 2013 , 121, 500-7	52
1129	Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. 2013 , 68, 68-94	186
1128	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. 2013 , 45, 12-7	300
1127	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. 2013 , 144, 829-40	317
1126	Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. 2013 , 14, 315-24	66

1125	Therapeutic targets in triple negative breast cancer. 2013 , 66, 530-42	104
1124	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). 2013 , 39, 252-60	57
1123	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. 2013 , 10, 34-42	243
1122	Mechanistic links between COPD and lung cancer. 2013 , 13, 233-45	272
1121	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. 2013 , 19, 279-90	649
1120	MicroRNA-365 regulates NKX2-1, a key mediator of lung cancer. 2013 , 335, 487-94	46
1119	The future of epigenetic therapy in solid tumours--lessons from the past. 2013 , 10, 256-66	262
1118	Jelly Belly trans-synaptic signaling to anaplastic lymphoma kinase regulates neurotransmission strength and synapse architecture. 2013 , 73, 189-208	16
1117	Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. 2013 , 20, 211-21	49
1116	Existing and emerging technologies for tumor genomic profiling. 2013 , 31, 1815-24	109
1115	Genomic sequencing in cancer. 2013 , 340, 161-70	20
1114	The role of high-throughput technologies in clinical cancer genomics. 2013 , 13, 167-81	19
1113	Implementing personalized cancer genomics in clinical trials. 2013 , 12, 358-69	231
1112	Novel therapeutic targets in non-small cell lung cancer. 2013 , 13, 394-401	59
1111	Translocations in normal B cells and cancers: insights from new technical approaches. 2013 , 117, 39-71	3
1110	New insights into the genetics of neuroblastoma. 2013 , 17, 63-9	26
1109	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. 2013 , 14, 590-8	475
1108	Identification of driver mutations in lung cancer: first step in personalized cancer. 2013 , 8, 3-14	20

1107	Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. 2013 , 56, 5675-90	307
1106	Genotype analysis of the NRF2 gene mutation in lung cancer. 2013 , 31, 1135-8	23
1105	Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma. 2013 , 104, 563-72	7
1104	ETS Fusion Genes in Prostate Cancer. 2013 , 139-183	4
1103	Pharmacogenomics in Cancer Therapeutics. 2013 , 89-116	
1102	Crizotinib for the treatment of non-small-cell lung cancer. 2013 , 70, 943-7	18
1101	Overcoming acquired resistance to kinase inhibition: the cases of EGFR, ALK and BRAF. 2013 , 23, 394-401	26
1100	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. 2013 , 368, 2385-94	2594
1099	Targeted therapy for non-small-cell lung cancer: past, present and future. 2013 , 13, 745-58	68
1098	Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer. 2013 , 49, 1876-81	16
1097	Acquired resistance to crizotinib from a mutation in CD74-ROS1. 2013 , 368, 2395-401	268
1096	Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. 2013 , 230, 270-6	94
1095	Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. 2013 , 81, 200-6	42
1094	Identification of cancer gene fusions based on advanced analysis of the human genome or transcriptome. 2013 , 7, 280-9	4
1093	Mouse models for lung cancer. 2013 , 7, 165-77	95
1092	Lung cancer biomarkers: State of the art. 2013 , 12, 3	64
1091	Molecular cytogenetics: recent developments and applications in cancer. 2013 , 84, 315-25	24
1090	Companion diagnostic testing for targeted cancer therapies: an overview. 2013 , 17, 515-23	13

1089	Sensitive detection of EML4-ALK fusion oncoprotein of lung cancer by in situ proximity ligation assay. 2013 , 51, 1843-8	1
1088	Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. 2013 , 6, 25-36	21
1087	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 , 15, 415-53	340
1086	Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance. 2013 , 238, 971-90	38
1085	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 , 137, 828-60	365
1084	High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma. 2013 , 109, 3084-91	20
1083	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. 2013 , 82, 31-7	42
1082	Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing. 2013 , 6, 546-53	22
1081	PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 2013 , 14, 597-608	6
1080	Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. 2013 , 463, 583-91	27
1079	Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten. 2013 , 19, 821-834	
1078	Impact of biomarkers on clinical trial risk. 2013 , 14, 1645-58	5
1077	Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. 2013 , 31, e15-7	53
1076	NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. 2013 , 32, 3009-18	99
1075	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 , 8, 823-59	632
1074	Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation. 2013 , 8, e96-8	13
1073	Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. 2013 , 6, 373-82	41
1072	Advances in personalized therapy for lung cancer. 2013 , 7, 475-85	8

1071	Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung. 2013 , 26, 1468-77	28
1070	[Targeted treatment of advanced lung cancer]. 2013 , 138, 2034-6	
1069	Molecular profiling in non-small cell lung cancer: a step toward personalized medicine. 2013 , 137, 481-91	40
1068	[Crizotinib - molecular therapy for lung cancer]. 2013 , 67, 205-8	3
1067	Médecine personnalisée en oncologie digestive. 2013 ,	
1066	Targeted therapy for non-small cell lung cancer. 2013 , 188, 907-12	19
1065	Prognostic value of LIPC in non-small cell lung carcinoma. 2013 , 12, 647-54	13
1064	Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. 2013 , 105, 686-93	40
1063	Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. 2013 , 2013, 757490	41
1062	Personalizing therapy in advanced non-small cell lung cancer. 2013 , 34, 822-36	14
1061	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. 2013 , 1, 575-581	37
1060	Genome Fusion Detection: a novel method to detect fusion genes from SNP-array data. 2013 , 29, 671-7	8
1059	Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. 2013 , 3, 430-43	174
1058	Targeted inhibition in tumors with ALK dependency. 2013 , 4, 1-8	1
1057	Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study. 2013 , 12, 12	28
1056	A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. 2013 , 50, 80-6	25
1055	Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada. 2013 , 20, 220-6	11
1054	Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer?. 2013 , 31, 2236-9	13

1053	Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. 2013 , 9, e1003464	82
1052	Triage of cytologic direct smears for ancillary studies: a case-based illustration and review. 2013 , 137, 1185-90	11
1051	The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment. 2013 , 6, pe13	51
1050	The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. 2013 , 25, 121-9	9
1049	Usefulness of transesophageal bronchoscopic ultrasound-guided fine-needle aspiration in the pathologic and molecular diagnosis of lung cancer lesions adjacent to the esophagus. 2013 , 20, 121-6	12
1048	Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. 2013 , 31, 2273-81	242
1047	Anaplastic lymphoma kinase (ALK1) immunohistochemistry in diagnostic dermatopathology; an update. 2013 , 35, 403-8; quiz 409-11	3
1046	Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment. 2013 , 19, 238-46	9
1045	How and when to use genetic markers for nonsmall cell lung cancer. 2013 , 19, 331-9	9
1044	Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. 2013 , 3, 630-5	383
1043	Personalized Treatment of Lung Adenocarcinoma. 2013 , 20, 309-314	
1042	Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer. 2013 , 19, 263-71	4
1041	Rare ALK expression but no ALK rearrangement in pancreatic ductal adenocarcinoma and neuroendocrine tumors. 2013 , 42, 949-51	5
1040	The new kid on the block: RET in lung cancer. 2013 , 3, 604-6	16
1039	The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. 2013 , 12, 890-900	54
1038	Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung. 2013 , 21, 476-82	16
1037	Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. 2013 , 31, 731-7	133
1036	Characteristics of rare diseases. 2013 , 55-99	1

1035	FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. 2013 , 19, 2572-83	174
1034	Novel targets in non-small cell lung cancer: ROS1 and RET fusions. 2013 , 18, 865-75	245
1033	Drug discovery in rare indications: opportunities and challenges. 2013 , 2013, 19-23	2
1032	Stratified medicine: drugs meet genetics. 2013 , 22, 53-7	12
1031	ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. 2013 , 12, 696-704	42
1030	Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. 2013 , 66, 705-7	40
1029	Translational Bioinformatics Approaches to Drug Development. 2013 , 2, 470-489	20
1028	Transforming mutations of RAC guanosine triphosphatases in human cancers. 2013 , 110, 3029-34	83
1027	Cytologic Features of ALK-Positive Pulmonary Adenocarcinoma. 2013 , 47, 252-7	9
1026	Emerging options for the management of non-small cell lung cancer. 2013 , 7, 221-34	14
1025	Data set for reporting of lung carcinomas: recommendations from International Collaboration on Cancer Reporting. 2013 , 137, 1054-62	18
1024	Targeted Therapy for Neuroblastoma: ALK Inhibitors. 2013 , 225, 303-8	24
1023	Salvage therapy beyond targeted therapy in lung adenocarcinoma. 2013 , 34, 837-44	5
1022	Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. 2013 , 39, 328-35	48
1021	EGFR and KRAS mutation analyses from specimens obtained by bronchoscopy and EBUS-TBNA. 2013 , 4, 264-272	4
1020	Subtyping of pulmonary adenocarcinoma in cytologic specimens: the next challenge. 2013 , 121, 601-4	5
1019	Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. 2013 , 26, 646-53	35
1018	Clinicians' views on introducing epidermal growth factor receptor testing in New Zealand. 2013 , 9, 249-56	2

1017	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. 2013 , 19, 3068-77	192
1016	Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives. 2013 , 13, 625-36	20
1015	Estado actual del tratamiento del c�ncer pulmonar. 2013 , 24, 611-625	
1014	RET, set, go. 2013 , 6, 326-326	
1013	Genomic medicine frontier in human solid tumors: prospects and challenges. 2013 , 31, 1874-84	90
1012	The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. 2013 , 2, e43	24
1011	Rare mutations in non-small-cell lung cancer. 2013 , 9, 699-711	17
1010	The heparin-binding growth factor midkine: the biological activities and candidate receptors. 2013 , 153, 511-21	87
1009	Impact of hydrolysis-mediated clearance on the pharmacokinetics of novel anaplastic lymphoma kinase inhibitors. 2013 , 41, 238-47	7
1008	Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. 2013 , 11, 140-8	50
1007	From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. 2013 , 105, 1441-56	41
1006	Conference Scene: 5th Asia Pacific Lung Cancer Conference. 2013 , 2, 31-33	
1005	SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers. 2013 , 3, 3012	18
1004	Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. 2013 , 8, 883-91	56
1003	The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. 2013 , 8, 1570-3	95
1002	Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone. 2013 , 8, 1004-11	76
1001	Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. 2013 , 8, 352-8	40
1000	MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. 2013 , 8, 574-81	42

999	STK10 missense mutations associated with anti-apoptotic function. 2013 , 30, 1542-8	11
998	Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma. 2013 , 122, 958-68	48
997	Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. 2013 , 8, e30-1	50
996	Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. 2013 , 8, 654-7	62
995	Gefitinib: re-emerging from the shadows. 2013 , 2, 423-437	
994	Effect of PF-02341066 and radiation on non-small cell lung cancer cells. 2013 , 29, 1094-100	18
993	Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation. 2013 , 8, e1-2	5
992	Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer. 2013 , 36, 342-7	3
991	The Potential Value of Immunohistochemistry as a Screening Tool for Oncogenic Targets of Personalized Lung Cancer Therapy. 2013 , 1, 82-92	5
990	Impact of the new EGF receptor and ALK testing guideline on personalized lung cancer medicine. 2013 , 10, 415-417	
989	Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. 2013 , 8, 45-51	225
988	mutations in lung cancer patients. 2013 , 6, 719-721	15
987	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. 2013 , 8, 415-22	126
986	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. 2013 , 8, 346-51	240
985	CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. 2013 , 30, 1675-80	14
984	Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. 2013 , 143, e30S-e39S	57
983	Research Highlights: Highlights from the latest articles in translating genomics to clinical practice in lung cancer. 2013 , 10, 329-331	
982	Conference Scene: Australia Lung Cancer Conference 2012: focus on systemic treatment of advanced non-small-cell lung cancer. 2013 , 2, 27-30	1

981	New methods for ALK status diagnosis in non-small-cell lung cancer: an improved ALK immunohistochemical assay and a new, Brightfield, dual ALK IHC-in situ hybridization assay. 2013 , 8, 1019-31	30
980	Ovarian cancer biomarker discovery based on genomic approaches. 2013 , 18, 298-312	15
979	EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report. 2013 , 6, 316-9	7
978	Molecular subtypes of non-small-cell lung cancer. 2013 , 6-20	1
977	[Pharmacology profile of crizotinib (Xalkori(®)Capsules) and clinical findings on this drug]. 2013 , 141, 106-13	1
976	ALK inhibitor. 2013 , 142, 48-50	
975	The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients. 2013 , 17, 484-92	4
974	Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. 2013 , 5, 91-101	13
973	Benefits, issues, and recommendations for personalized medicine in oncology in Canada. 2013 , 20, e475-83	21
972	Biopsy and mutation detection strategies in non-small cell lung cancer. 2013 , 75, 181-7	10
971	Clinical use of crizotinib for the treatment of non-small cell lung cancer. 2013 , 7, 91-101	19
970	MET overexpression and gene amplification in NSCLC: a clinical perspective. 2013 , 4, 15-25	5
969	Overview of ALK and ROS1 Rearranged Lung Cancer. 2013 , 75, 236-7	5
968	EXPERIMENTAL CARDIOVASCULAR AND LUNG RESEARCH From mutation to methylation □ molecular markers in lung cancer. 2013 , 2, 148-153	
967	Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment. 2013 , 32, 594-603	68
966	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. 2013 , 8, e52093	82
965	Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. 2013 , 8, e52261	58
964	EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. 2013 , 8, e56011	61

963	Systematic identification of combinatorial drivers and targets in cancer cell lines. 2013 , 8, e60339	6
962	ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. 2013 , 8, e69016	49
961	A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. 2013 , 8, e69794	33
960	Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. 2013 , 8, e70839	79
959	Galectin-4, a novel predictor for lymph node metastasis in lung adenocarcinoma. 2013 , 8, e81883	33
958	In situ Protein Detection for Companion Diagnostics. 2013 , 3, 271	8
957	Cancer outlier analysis based on mixture modeling of gene expression data. 2013 , 2013, 693901	3
956	Biomarkers in Lung Cancer: Integration with Radiogenomics Data. 2013 ,	1
955	ALK: Anaplastic lymphoma kinase. 162-189	0
954	Lung cancer. 506-525	
953	Molecular oncology of neuroblastoma. 669-678	
952	Fishing for ALK with immunohistochemistry may predict response to crizotinib. 2013 , 99, e229-e232	5
951	Adenocarcinoma of the lung. 1043-1092	1
950	Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer. 2013 , 2013,	22
949	Close Neighbours on Chromosome 2 the ALK and MYCN Genes. Implications for Targeted Therapeutics in Neuroblastoma. 2013 ,	
948	Lung cancer in 2013: state of the art therapy for metastatic disease. 2013 , 339-46	8
947	Current Issues in Lung Cancer Pathology. 2014 , 34, 10	1
946	Molecular pathology of lung cancer: current status and future directions. 2014 , 77, 49-54	9

945	ALK-driven tumors and targeted therapy: focus on crizotinib. 2014 , 7, 87-94	11
944	Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. 2014 , 7, 1689-704	54
943	Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. 2014 , 9, e99409	139
942	Identification of ALK gene alterations in urothelial carcinoma. 2014 , 9, e103325	8
941	Phase I/II Study of Alectinib (CH5424802/RO5424802) in Patients with ALK-rearranged Non-small Cell Lung Cancer (NSCLC): Updated Results from the AF-001JP Trial. 2014 , 54, 892-897	1
940	The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy. 2014 , 9, e84501	19
939	NTRK1 fusion in glioblastoma multiforme. 2014 , 9, e91940	69
938	Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening. 2014 , 9, e92828	30
937	Fusion FISH imaging: single-molecule detection of gene fusion transcripts in situ. 2014 , 9, e93488	21
936	Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues reveals a link to tumor progression. 2014 , 9, e94202	14
935	Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. 2014 , 9, e101551	43
934	The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization. 2014 , 9, e112159	24
933	Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients. 2014 , 9, e114008	17
932	The Human Genome Project and Personalized Medicine. 2014 , 3418-3422	
931	The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. 2014 , 5, 5750-63	27
930	Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. 2014 , 5, 1048-54	45
929	Molecular pathways and therapeutic targets in lung cancer. 2014 , 5, 1392-433	135
928	Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. 2014 , 8, 1037-46	9

927	Identification of novel fusion genes with 28S ribosomal DNA in hematologic malignancies. 2014 , 44, 1193-8	5
926	Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. 2014 , 7, 375-85	20
925	Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer. 2014 , 77, 258-61	11
924	A Favorable Treatment Response of Erlotinib in Lung Adenocarcinoma with Concomitant Activating EGFR Mutation and ROS1 Rearrangement. 2014 , 37, 46	
923	Molecular Biology of Non-small-cell Lung Cancer. 2014 , 34, 4	2
922	Combined effects of asbestos and cigarette smoke on the development of lung adenocarcinoma: different carcinogens may cause different genomic changes. 2014 , 32, 475-82	12
921	Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma. 2014 , 7, 2127-32	14
920	New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer. 2014 , 5, 35-42	
919	Molecular Targeted Therapy in Lung Cancer. 2014 , 34, 37	1
918	Management and future directions in non-small cell lung cancer with known activating mutations. 2014 , e353-65	62
917	50 Years of progress in the systemic therapy of non-small cell lung cancer. 2014 , 177-89	75
916	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. 2014 , 14, 807-15	14
915	ALK-positive cancer: still a growing entity. 2014 , 10, 305-21	9
914	Application of Novel Genotyping Microarray Technologies in Cancer Research. 2014 , 47-73	
913	Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. 2014 , 15, 1613-21	57
912	Patterns of ALK expression in different human cancer types. 2014 , 67, 477-81	5
911	Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. 2014 , 74, 1023-8	179
910	The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials. 2014 , 14, 683	36

909	Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical Epropeller domain. 2014 , 111, 5195-200	70
908	Expression of transcript factors SALL4 and OCT4 in a subset of non-small cell lung carcinomas (NSCLC). 2014 , 2, 10	14
907	Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. 2014 , 14, 834	12
906	Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target. 2014 , 15, 128-34	15
905	Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry. 2014 , 33, 109	17
904	Management of NSCLC: focus on crizotinib. 2014 , 15, 2587-97	13
903	Evaluating the utility of local therapy for oligometastatic lung cancer. 2014 , 3, 373-381	
902	Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. 2014 , 5, e1564	64
901	From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience. 2014 , 4, 315-324	1
900	RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. 2014 , 110, 1571-8	97
899	Oncogenic RIT1 mutations in lung adenocarcinoma. 2014 , 33, 4418-23	56
898	Successes and limitations of targeted cancer therapy in lung cancer. 2014 , 41, 62-77	26
897	Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis?. 2014 , 18, 615-24	26
896	Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?. 2014 , 18, 983-5	6
895	Pathologie als Gatekeeper. 2014 , 20, 933-942	
894	Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. 2014 , 10, 2081-96	13
893	Kinase Inhibitors in Cancer. 2014 ,	2
892	Targeting molecular addictions in cancer. 2014 , 111, 2033-8	28

891	Identification of mutant genes with high-frequency, high-risk, and high-expression in lung adenocarcinoma. 2014 , 5, 211-8	10
890	Analysis of clinicopathological features of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non-small-cell lung cancer. 2014 , 5, 255-60	3
889	Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. 2014 , 5, 3116	394
888	Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. 2014 , 90, 228-35	4
887	P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape. 2014 , 10, e1003729	77
886	Lung cancer: dropping bars or rising hoops--phase III outcomes of NSCLC. 2014 , 11, 381-2	1
885	Synergistic antitumor effect of a combination of paclitaxel and carboplatin with nobiletin from <i>Citrus depressa</i> on non-small-cell lung cancer cell lines. 2014 , 80, 452-7	19
884	Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China. 2014 , 5, 1-9	27
883	Managing treatment-related adverse events associated with Alk inhibitors. 2014 , 21, 19-26	52
882	Differential expression of and genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status. 2014 , 2, 481-489	3
881	Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement. 2014 , 9, 3	30
880	Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas. 2014 , 12, e1001784	11
879	Integrating in silico prediction methods, molecular docking, and molecular dynamics simulation to predict the impact of ALK missense mutations in structural perspective. 2014 , 2014, 895831	29
878	The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. 2014 , 13, 329-40	57
877	Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement. 2014 , 8, 2155-2159	4
876	Thoracic Neoplasia: Carcinoma. 2014 , 2677-2689	
875	Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. 2014 , 4, 190	39
874	Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. 2014 , 5, 252	31

873	Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer. 2014 , 4, 281	23
872	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. 2014 , 4, 204	111
871	Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase. 2014 , 69	2
870	Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. 2014 , 9, 1726-8	13
869	Multiplexed molecular profiling of lung cancer using pleural effusion. 2014 , 9, 1048-1052	31
868	Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. 2014 , 45, 1430-6	38
867	Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. 2014 , 32, 33-9	5
866	First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. 2014 , 10, 1081-93	5
865	Current status and study activity of lung cancer in Japan. 2014 , 52, 315-6	
864	Breast cancer: post-mastectomy radiotherapy reduces recurrence and mortality. 2014 , 11, 382-4	19
863	Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. 2014 , 20, 6551-8	67
862	Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma. 2014 , 5, 411-6	3
861	Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. 2014 , 5, 5893	100
860	Personalized oncology: genomic screening in phase 1. 2014 , 122, 723-33	16
859	Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. 2014 , 15, 2693-708	18
858	Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. 2014 , 32, 2780-7	136
857	National Working Group Meeting on ALK diagnostics in lung cancer. 2014 , 10 Suppl 2, 11-7	9
856	ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. 2014 , 272, 568-76	112

855	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. 2014 , 128, 879-91	46
854	Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer. 2014 , 32, 4050-8	79
853	Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements--comparison of multiple immunohistochemical methods. 2014 , 65, 539-48	27
852	Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. 2014 , 138, 794-802	28
851	First-line crizotinib versus chemotherapy in ALK-positive lung cancer. 2014 , 371, 2167-77	2116
850	ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. 2014 , 138, 1449-58	73
849	Comprehensive exploration of novel chimeric transcripts in clear cell renal cell carcinomas using whole transcriptome analysis. 2014 , 53, 1018-32	25
848	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. 2014 , 20, 1383-92	121
847	Molecular alterations in non-small-cell lung cancer: perspective for targeted therapy and specimen management for the bronchoscopist. 2014 , 19, 1117-25	10
846	Molecular alterations in non-small cell lung carcinomas of the young. 2014 , 45, 2379-87	32
845	A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. 2014 , 799, 85-117	76
844	Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer. 2014 , 44, 575-80	7
843	Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. 2014 , 65, 398-407	49
842	In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers. 2014 , 234, 253-61	11
841	Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape. 2014 , 10 Suppl 2, 2-10	3
840	Identification of somatic alterations in stage I lung adenocarcinomas by next-generation sequencing. 2014 , 53, 289-98	9
839	The evolving genomic classification of lung cancer. 2014 , 232, 121-33	74
838	ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis. 2014 , 74, 6094-106	39

837	Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. 2014 , 9, 1219-27	149
836	Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR. 2014 , 135, 2962-71	35
835	Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma. 2014 , 122, 810-21	26
834	Molecular profiling and companion diagnostics: where is personalized medicine in cancer heading?. 2014 , 11, 761-771	4
833	Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas. 2014 , 141, 420-8	18
832	ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. 2014 , 12, 111-8	90
831	Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. 2014 , 351, 67-76	23
830	Pharmacotherapy targeting the EGFR oncogene in NSCLC. 2014 , 15, 2293-305	16
829	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. 2014 , 311, 1998-2006	1042
828	[Mutational tumor profiles beyond organ and tissue specificity: implications for diagnostics and clinical study design]. 2014 , 35 Suppl 2, 277-80	2
827	Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer. 2014 , 8, 97	47
826	Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. 2014 , 9, 1171-9	57
825	VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy?. 2014 , 38, 858-63	67
824	Molecular Testing of Lung Carcinomas. 2014 , 19, 36-39	
823	An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. 2014 , 9, 631-8	120
822	Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay. 2014 , 9, 307-15	23
821	A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers. 2014 , 15, 721-34	11
820	Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer after crizotinib therapy. 2014 , 2014, 11-2	12

819	Present and future molecular testing of lung carcinoma. 2014 , 21, 94-9	17
818	High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer. 2014 , 9, 646-53	24
817	Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. 2014 , 9, 248-53	11
816	HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. 2014 , 9, 285-94	68
815	Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. 2014 , 38, 1681-8	22
814	ALK testing in non-small cell lung carcinoma: what now?. 2014 , 9, 593-5	8
813	Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients. 2014 , 9, 1816-20	14
812	Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. 2014 , 9, 295-306	130
811	MEK inhibitor for gastric cancer with MEK1 gene mutations. 2014 , 13, 3098-106	15
810	Construction of mate pair full-length cDNAs libraries and characterization of transcriptional start sites and termination sites. 2014 , 42, e125	8
809	Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. 2014 , 42, 13557-72	74
808	Large-cell carcinoma of the lung: a diagnostic category redefined by immunohistochemistry and genomics. 2014 , 20, 324-31	22
807	ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. 2014 , 9, 729-32	39
806	Practice makes perfect protocols: the Canadian anaplastic lymphoma kinase study. 2014 , 9, 1237-9	1
805	Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. 2014 , 9, 1255-63	61
804	Forty years of the international association for study of lung cancer pathology committee. 2014 , 9, 1740-9	4
803	Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. 2014 , 9, 18-25	55
802	ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. 2014 , 9, 1470-6	19

801	Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. 2014 , 9, 1685-92	52
800	Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. 2014 , 46, 383-8	26
799	A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line. 2014 , 9, 1638-46	12
798	Breaking down RET breakpoints in lung adenocarcinoma. 2014 , 9, 590-2	1
797	FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. 2014 , 19, e5-11	174
796	ALK inhibitors and advanced non-small cell lung cancer (review). 2014 , 45, 499-508	30
795	Flotillin-1 regulates oncogenic signaling in neuroblastoma cells by regulating ALK membrane association. 2014 , 74, 3790-801	17
794	FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism. 2014 , 12, 1042-54	55
793	A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene. 2014 , 44, 963-8	10
792	Targeted chemotherapy, the medical ecosystem, and the future of American health care. 2014 , 57, 268-84	1
791	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. 2014 , 25, 1681-1690	208
790	Preparation of cell blocks for lung cancer diagnosis and prediction: protocol and experience of a high-volume center. 2014 , 87, 432-8	20
789	Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. 2014 , 4, 78	60
788	Evidence that the lung Adenocarcinoma EML4-ALK fusion gene is not caused by exposure to secondhand tobacco smoke during childhood. 2014 , 23, 1432-1434	3
787	Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. 2014 , 6, 423-32	90
786	A Novel Cryptic Three-Way Translocation t(2;9;18)(p23.2;p21.3;q21.33) with Deletion of Tumor Suppressor Genes in 9p21.3 and 13q14 in a T-Cell Acute Lymphoblastic Leukemia. 2014 , 2014, 357123	7
785	A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. 2014 , 4, 174	20
784	Chemotherapy in Metastatic NSCLC - New Regimens (Pemetrexed, Nab-Paclitaxel). 2014 , 4, 177	5

783	Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective. 2014 , 4, 182	14
782	Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement-positive lung adenocarcinoma: A case report. 2014 , 2, 121-123	9
781	Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group. 2014 , 48, 1-9	18
780	Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment. 2014 , 8, 145-52	5
779	Genetic polymorphisms and non-small-cell lung cancer: future paradigms. 2014 , 12, 524-6	4
778	nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. 2014 , 14, 129-41	13
777	Secondary EML4-ALK-positive lung adenocarcinoma in a patient previously treated for acute lymphoblastic leukemia in childhood: a case report. 2014 , 44, 593-6	1
776	ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. 2014 , 9, 464-8	51
775	A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material. 2014 , 9, 769-74	37
774	Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test. 2014 , 9, 1464-9	14
773	NSCLC and HER2: between lights and shadows. 2014 , 9, 1750-62	43
772	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. 2014 , 134, 1484-94	106
771	Detection of gene rearrangements in targeted clinical next-generation sequencing. 2014 , 16, 405-17	59
770	Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. 2014 , 83, 389-95	50
769	Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. 2014 , 88, 892-8	136
768	Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. 2014 , 83, 259-64	26
767	Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing. 2014 , 84, 215-21	25
766	FuseFISH: robust detection of transcribed gene fusions in single cells. 2014 , 6, 18-23	32

765	Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. 2014 , 41, 110-25	53
764	RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia. 2014 , 207, 40-5	15
763	TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC. 2014 , 85, 25-30	10
762	Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer. 2014 , 41, 57-68	16
761	Omics-based nanomedicine: the future of personalized oncology. 2014 , 352, 126-36	55
760	Application of Translational Science to Clinical Development. 2014 , 1-21	
759	Prognostic and predictive biomarkers: tools in personalized oncology. 2014 , 18, 273-84	102
758	Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. 2014 , 38, 1296-305	42
757	RETRACTED: Ca(2+)/calmodulin-dependent protein kinase II α a critical mediator of the NF- κ B network, is a novel therapeutic target in non-small cell lung cancer. 2014 , 344, 119-128	17
756	Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options. 2014 , 89, 358-65	23
755	Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. 2014 , 140, 589-98	28
754	Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. 2014 , 2, 43-53	3
753	Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. 2014 , 140, 453-60	32
752	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. 2014 , 83, 37-43	68
751	Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. 2014 , 57, 1170-87	79
750	Overcoming drug resistance in ALK-rearranged lung cancer. 2014 , 370, 1250-1	22
749	Targeted genomic rearrangements using CRISPR/Cas technology. 2014 , 5, 3728	203
748	Systems analysis of human multigene disorders. Preface. 2014 , 799, v - viii	3

747	A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. 2014 , 13, 1918-28	69
746	Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors. 2014 , 22, 1303-12	15
745	Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer. 2014 , 15, e33-5	13
744	Molecular Testing in Cancer. 2014 ,	1
743	Pharmacogenomics and Personalized Medicines in Cancer Treatment. 2014 , 55-90	
742	3D-QSAR and molecular fragment replacement study on diaminopyrimidine and pyrrolotriazine ALK inhibitors. 2014 , 1067, 127-137	9
741	ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. 2014 , 120, 2392-402	46
740	Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzopyrido[1,2-a]pyrimidin-10(9H)-one (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant	37
739	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. 2014 , 232, 274-82	40
738	Genomics and Molecular Profiling of Lung Cancer. 2014 , 193-211	
737	Protein kinase inhibitors to treat non-small-cell lung cancer. 2014 , 15, 1203-13	16
736	Pharmacodynamic biomarkers: falling short of the mark?. 2014 , 20, 2587-94	35
735	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. 2014 , 4, 662-673	591
734	Recent clinical advances in lung cancer management. 2014 , 32, 973-82	169
733	DNA sequencing of cancer: what have we learned?. 2014 , 65, 63-79	37
732	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. 2014 , 25, 415-22	166
731	Molecularly targeted cancer therapy: some lessons from the past decade. 2014 , 35, 41-50	206
730	Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. 2014 , 20, 11-28	48

729	Lipase member H is a novel secreted protein selectively upregulated in human lung adenocarcinomas and bronchioloalveolar carcinomas. 2014 , 443, 1141-7	13
728	New treatment options for lung adenocarcinoma--in view of molecular background. 2014 , 20, 11-25	26
727	Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. 2014 , 6, 219ra9	120
726	Section IV: non-small cell lung cancer and malignant melanoma. 2014 , 38, 180-98	2
725	Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy. 2014 , 3, 118-23	16
724	Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma. 2014 , 53, 183-93	117
723	ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. 2014 , 26, 682-94	236
722	Aspects biologiques des cancers bronchiques. 2014 , 6, 311-319	
721	Thérapies ciblées : comment déterminer la cible ?. 2014 , 6, 453-458	
720	Thérapies ciblées : quel traitement pour quel patient ?. 2014 , 6, 459-469	
719	Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance. 2014 , 52, 330-8	12
718	Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. 2014 , 122, 445-53	38
717	ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma. 2014 , 105, 490-7	24
716	Application of genotype-guided cancer therapy in solid tumors. 2014 , 15, 79-93	17
715	Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. 2014 , 13, 475-82	42
714	Liquid biopsies in lung cancer: the new ambrosia of researchers. 2014 , 1846, 539-46	95
713	EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC). 2014 , 86, 158-63	41
712	Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?. 2014 , 86, 190-4	52

711	Novel agents in development for advanced non-small cell lung cancer. 2014 , 6, 240-53	26
710	Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery. 2014 , 5, 1266-1279	19
709	In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. <i>Nature</i> , 2014 , 516, 423-7	504 407
708	The landscape of kinase fusions in cancer. 2014 , 5, 4846	586
707	Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers. 2014 , 20, 4193-9	20
706	Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses. 2014 , 96, 182-91	17
705	Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer. 2014 , 35, 9759-67	13
704	Nucleic acid-based tissue biomarkers of urologic malignancies. 2014 , 51, 173-99	28
703	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. 2014 , 20, 5686-96	227
702	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. 2014 , 15, 1119-28	523
701	Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. 2014 , 19, 616-22	80
700	Update on systemic therapy of advanced non-small-cell lung cancer. 2014 , 14, 1189-203	19
699	Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. 2014 , 32, 1012-9	74
698	Recurrence of lung adenocarcinoma after an interval of 15 years revealed by demonstration of the same type of EML4-ALK fusion gene. 2014 , 210, 1112-6	8
697	Translating genomics for precision cancer medicine. 2014 , 15, 395-415	56
696	Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. 2014 , 27, 214-21	72
695	Somatic alterations as the basis for resistance to targeted therapies. 2014 , 232, 244-54	27
694	Non-small-cell lung cancers: a heterogeneous set of diseases. 2014 , 14, 535-46	934

693	U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. 2014 , 20, 2029-34	101
692	Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. 2014 , 36, 829-841	14
691	Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. 2014 , 111, 4233-8	191
690	New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. 2014 , 20, 4425-35	21
689	Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. 2014 , 5, 4577	88
688	nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update. 2014 , 15, 391-7	9
687	Assessing the hodgepodge of non-mapped reads in bacterial transcriptomes: real or artifactual RNA chimeras?. 2014 , 15, 633	3
686	Crizotinib: A comprehensive review. 2013 , 2, 91-7	80
685	Determining factors of endobronchial ultrasound-guided transbronchial needle aspiration specimens for lung cancer subtyping and molecular testing. 2019 , 8, 404-411	9
684	A comparative analysis of immunohistochemistry and fluorescent hybridization assay to detect anaplastic lymphoma kinase status in lung adenocarcinoma cases: A search for a testing algorithm. 2017 , 54, 148-154	4
683	Targeted therapy in nonsmall cell lung cancer. 2017 , 54, 83-88	5
682	New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer. 2017 , 54, 203-208	4
681	A Comparative Study of Cell Block versus Biopsy for Detection of Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangement in Adenocarcinoma Lung. 2019 , 36, 13-17	3
680	Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung. 2018 , 7, 61-64	2
679	Clinicopathological and molecular epidemiological study of lung cancer patients seen at a tertiary care hospital in Northern India. 2017 , 6, 171-175	2
678	Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: Using immunohistochemistry as the diagnostic modality in a significant subset. 2017 , 6, 169-170	3
677	Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma. 2015 , 49, 310-7	19
676	Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. 2016 , 50, 197-203	57

675	Present status and problems on molecular targeted therapy of cancer. 2012 , 44, 1-10	22
674	Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer. 2012 , 44, 74-84	9
673	SEC31A-ALK Fusion Gene in Lung Adenocarcinoma. 2016 , 48, 398-402	22
672	NFATC3-PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines. 2019 , 51, 391-401	8
671	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. 2019 , 51, 1231-1240	9
670	Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment. 2015 , 04, 53-57	1
669	About the Feasibility of Personalized Medicine in a Low Income Country?. 2015 , 03, 41-45	2
668	Design and Synthesis of an Anticancer Diarylurea Derivative with Multiple-Kinase Inhibitory Effect. 2012 , 33, 1571-1576	12
667	Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer: A case report and review of literature. 2020 , 11, 495-503	5
666	Apoptosis block as a barrier to effective therapy in non small cell lung cancer. 2014 , 5, 588-94	20
665	Pros and cons of using aberrant glycosylation as companion biomarkers for therapeutics in cancer. 2011 , 44, 765-71	14
664	Chimeric RNAs as potential biomarkers for tumor diagnosis. 2012 , 45, 133-40	13
663	Non-small cell lung cancer--genetic predictors. 2013 , 157, 125-36	30
662	East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. 2011 , 30, 287-92	159
661	Recent progress of genome study for anaplastic thyroid cancer. 2013 , 11, 68-75	22
660	New lung cancer panel for high-throughput targeted resequencing. 2014 , 12, 50-7	5
659	FusionScan: accurate prediction of fusion genes from RNA-Seq data. 2019 , 17, e26	6
658	Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. 2010 , 134, 55-65	25

657	Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?. 2010 , 134, 66-72	70
656	The immunohistochemistry laboratory: looking at molecules and preparing for tomorrow. 2010 , 134, 1659-65	23
655	Molecular testing of solid tumors. 2011 , 135, 67-82	28
654	Anaplastic large cell lymphoma: twenty-five years of discovery. 2011 , 135, 19-43	83
653	Molecular diagnostics of lung carcinomas. 2011 , 135, 622-9	21
652	Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. 2011 , 135, 655-64	27
651	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. 2013 , 2, 265-282	41
650	Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors. 2019 , 17, 297-301	13
649	Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer. 2014 , 10, 658-63	2
648	Anaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalized therapy. 2013 , 68, 726	2
647	Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non- small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies. 2014 , 15, 3057-63	22
646	Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients. 2014 , 15, 3927-32	11
645	A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer. 2015 , 16, 4797-800	4
644	Clinical efficacy and possible applications of genomics in lung cancer. 2015 , 16, 1693-8	1
643	Prioritisation of structural variant calls in cancer genomes. 2017 , 5, e3166	10
642	Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. 2016 , 8, e513	14
641	Biomarkers. 2021 , 43-64	
640	[Angiomatoid fibrous histiocytoma: a literature review and a report of two cases]. 2021 , 83, 31-38	

- 639 Les patients ALK et ROS1 : quelle séquence ? : ALK and ROS1 patients: what sequence?. **2021**, 13, 2S174-2S184
- 638 Oncogène pulmonaire : mécanismes génétiques et addictions oncogéniques. **2021**, 13, 2S12-2S20
- 637 Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review. **2021**, 14, 5107-5113 1
- 636 Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC. **2021**, 2
- 635 Aberrant Signaling Pathways in Sinonasal Intestinal-Type Adenocarcinoma. **2021**, 13, 2
- 634 Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation. **2021**, 22, e53693 4
- 633 New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer. **2021**, 13, 1
- 632 Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities.
- 631 A novel 3' truncated ALK cause ALK + in a patient with minimally invasive adenocarcinoma. **2021**, 1
- 630 Neuroblastoma. **2009**, 507-540 2
- 629 Recent Advances in Cancer Genomics and Cancer-Associated Genes Discovery. **2010**, 11-29
- 628 Molecular Pathology of Lung Cancer. **2010**, 1-25 1
- 627 Discovery of a Lung Cancer Oncogene, EML4-ALK, and Its Clinical Application. **2010**, 50, 889-893
- 626 Abstract PL2-1: The impact of genomic changes on the treatment of lung cancer. **2010**,
- 625 Molecular Pathology of Mature B-Cell and T-Cell Lymphomas. **2011**, 157-214
- 624 Respiratory tract. **2011**, 291-436 1
- 623 Lymph nodes. **2011**, 1771-1899
- 622 The Techniques of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. **2011**, 6, 57-64

621 Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine. **2012**, 569-589

620 Advanced Neuroblastoma: Role of ALK Mutations. **2012**, 199-207

619 Lung Cancer. **2012**, 151-165

618 Somatic Alterations and Targeted Therapy. **2012**, 51-101

617 A Strategy for the Lung Cancer Treatment in Elderly Patients. **2012**, 63, 374-382

616 Targeted Therapies for Non-small-Cell Lung Cancer. **2012**, 93-114

615 A Case of Adenocarcinoma of the Lung Successfully Treated with Pemetrexed as Fourth-line Chemotherapy for Multiple Liver Metastases After Acquired Resistance to Crizotinib. **2012**, 52, 242-247

614 Discovery of the EML4-ALK Fusion Oncogene; an Effective Target in Lung Cancer. **2012**, 52, 136-141

613 Treatment of non-small cell lung cancer in the era of targeted therapy. **2012**, 01, 1-4

612 Molecular Targeted Therapy of Lung Cancer. **2012**, 99-107

611 How Should Targeting Agents Be Used?. **2012**, 52, 142-152

1

610 [Screening and identification of anoikis-resistant gene UBCH7 in esophageal cancer cells]. **2012**, 34, 190-7

1

609 Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer among atomic-bomb survivors. 120622084931008

608 Oncogenic driver mutations. **2012**, 45-58

607 Predictive Markers in Lung Cancer. **2013**, 43-68

606 Fluorescence In Situ Hybridization (FISH). **2013**, 415-439

605 T-Cell Malignancies in Children and Adolescents: State of the Clinical and Biological Science. **2013**, 179-216

604 Malignant Lymphomas Involving Lung and Pleura. **2013**, 319-347

603 HGFR/MET and ALK inhibitors. **2012**, 72-86

602 Genome-Wide Analysis and Gene Expression Profiling of Neuroblastoma: What Contribution Did They Give to the Tumor Treatment?. **2013**, 571-582

601 Futurs biomarqueurs et cibles thérapeutiques : c-MET, MEK et ALK. **2013**, 363-372

600 CHAPTER 13. Hsp90 Inhibitors in Clinic. **2013**, 336-378

599 Multiple functions of a glioblastoma fusion oncogene. **2013**, 123, 548-51

4

598 A case of ALK-positive lung cancer effectively diagnosed by cell block preparation. **2013**, 52, 346-349

597 Discordant tumor response in the treatment of ALK-rearranged non-small cell lung cancer leads to the diagnosis of synchronous multiple primary lung cancer. **2013**, 02, 16-19

596 Next-Generation Sequencing for Cancer Genomics. **2013**, 55-74

1

595 TYPES OF DNA DAMAGE. **2013**, 115-118

594 Systemic Therapy for Lung Cancer. **2013**, 125-135

593 Successful Treatment with Crizotinib in a Case of Lung Adenocarcinoma Positive on ALK Immunohistochemistry but Indeterminate on EML4-ALK Fluorescence In Situ Hybridization. **2013**, 53, 893-898

592 [Role of diagnostic imaging in thoracic surgery]. **2013**, 69, 427-33

591 EML4-ALK Fusion Gene and Therapy with ALK-Targeted Agents in Non-Small Cell Lung Cancer. **2013**, 449-472

590 Novel agents in development and future directions. **2013**, 214-235

589 Epidermal Growth Factor Receptor Testing in Lung Adenocarcinoma. **2014**, 15-22

588 Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. **2014**, 75-118

587 Role of Next-Generation Sequencing Technologies. **2013**, 1-16

586 The Biology of Lysine Acetylation Integrates Transcriptional Programming and Metabolism. **2013**, 141-166

- 585 The Role of Phase III Trials in Modern Drug Development. **2014**, 763-783
- 584 Longcarcinom. **2014**, 117-124
- 583 Crizotinib in non-small cell lung cancer. **2014**, 03, 5-9
- 582 Molecular Testing in Pulmonary Tumors. **2014**, 211-228
- 581 Pathology, Biomarkers, and Molecular Diagnostics. **2014**, 226-252.e6
- 580 Introduction. **2014**, 1-6
- 579 Case of an 18-year-old Female with EML4-ALK-positive Lung Adenocarcinoma. **2014**, 54, 153-157 3
- 578 Two Cases of Synchronous Multiple Lung Cancer Harboring Different Mutations; EGFR or ALK. **2014**, 54, 146-152 1
- 577 Current status and perspectives of molecular target therapy for advanced lung cancer. **2014**, 60, 328-334
- 576 Intracellular Signaling. **2014**, 22-39.e8
- 575 Pharmacogenomics in Molecular Oncology. **2014**, 405-421
- 574 Diagnostic moléculaire des tumeurs solides. **2014**, 39-56
- 573 Different ALK Results Between Two Examinations in a Case of EML4-ALK-positive Lung Cancer. **2014**, 54, 206-211
- 572 Induction therapy followed by surgery for non small-cell lung cancer. **2014**, 126, 103-107
- 571 Cytogenetics. **2014**, 17-60
- 570 The Future of Cancer Clinical Trials Systems. **2014**, 60, 210-219
- 569 The 2013 Incentive Award of the Okayama Medical Association in Cancer Research (2013 Hayashibara Prize and Yamada Prize). **2014**, 126, 191-194
- 568 Problems with the Diagnosis and Treatment of Patients with ALK-rearranged NSCLC in the Clinical Setting. **2014**, 54, 879-886

567 ????? ???? Anaplastic Lymphoma Kinase ??? ?? ???? **2014**, 2, 64-67

566 Strategies in ALK Rearranged NSCLC Patients. **2015**, 147-156

565 Strategies in Patients with Other Molecular Alterations. **2015**, 187-202

564 PET imaging for tyrosine kinase inhibitor (TKI) biodistribution in mice. **2015**, 1219, 199-206

563 Genomic Applications in Pulmonary Malignancies. **2015**, 383-413

562 Role of Immunohistochemistry in the Detection of Targetable Mutations. **2015**, 109-127

1

561 Adequacy and Utilization of Small Biopsy Material for Molecular Diagnosis. **2015**, 97-108

560 Past and Current Developments in ALK-TKI Resistant NSCLC. **2015**, 55, 936-940

559 Chromosomal Translocations in Lung Cancer. **2015**, 403-416

558 Pharmacogenetics and Antineoplastic Therapies. **2015**, 275-305

557 Lung Cancer: Diagnosis and Treatment Approach. **2015**, 97-144

2

556 Epidemiology and Mechanism of Carcinogenesis of the Retrovirus HIV. **2015**, 83-94

555 Promoter Methylation of the <i>CADM1</i> and <i>4.1B</i> Genes Occurs Independently of the <i>EGFR</i> or the <i>KRAS</i> Mutation in Non-Small Cell Lung Cancer. **2015**, 06, 273-285

554 Targeted Therapies for Non-Small Cell Lung Cancer. **2015**, 89-101

1

553 A cytological study of EML4-ALK mutations in lung cancer. **2015**, 54, 187-191

552 Tumors of the lung. 361-372

551 Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer. **2015**, 16, 5521-4

5

550 A Case of ALK-rearrangement-positive Lung Adenocarcinoma Successfully Treated with Crizotinib for Rapid Progression After the Discontinuation of Alectinib. **2016**, 56, 308-313

1

549 ALK Gene Rearrangements and Mutations. **2016**, 4-2-4-3

548 Molecular Targeted Anticancer Drugs. **2016**, 175-238

547 [The Cutting-edge of Medicine; Clinico-pathogenetic background and approach for early detection of lung cancer]. **2016**, 105, 105-11

546 Genetic Testing in Lung Cancer Treatment. **2016**, 56, 242-245

545 Drug interaction (36. Combination with oral molecular target drugs in lung cancer). **2016**, 128, 141-146

544 Biomarkers for Lung Cancer: Focusing on Targeted Drug Resistance. **2016**, 56, 55-60

543 Molecular Biomarkers in Pulmonary Cytology. **2016**, 121-138

542 PET/CT of Lung Cancer. **2016**, 241-266

1

541 Lung Cancer. **2016**, 419-432

540 Lung Cancer Among Asian Americans. **2016**, 107-136

539 Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. **2016**, 27-107

538 The landscape of gene fusions in hepatocellular carcinoma.

537 Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables. **2016**, 37, 189-95

3

536 Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. **2016**, 7, 514-524

1

535 Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer.

534 Prioritisation of Structural Variant Calls in Cancer Genomes.

533 Personalized Medicine for the Treatment of Human Cancer. **2017**, 843-855

532 The 2015 Incentive Award of the Okayama Medical Association in Cancer Research (2015 Hayashibara Prize and Yamada Prize). **2017**, 129, 5-8

- 531 Toward Precision Medicine in Gynecology and Obstetrics. **2017**, 1-8
- 530 Methods in Molecular Diagnosis. **2017**, 63-77
- 529 Cell Proliferation and Differentiation. **2017**, 11-35
- 528 EGFR Mutant. **2017**, 167-189
- 527 Accurate Nodal Staging and Biomarker Testing with Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. **2017**, 79-96
- 526 Development of a new choroidal metastasis in resistance to crizotinib therapy in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. **2017**, 10, 310-314 3
- 525 Dividing and conquering the variation among variants in lung cancer. **2017**, 6, S369-S370
- 524 An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.
- 523 I. Diagnosis of the Molecular Aberrations in Non-small Cell Cancer. **2017**, 106, 1082-1088
- 522 Computational proteogenomic identification and functional interpretation of translated fusions and micro structural variations in cancer.
- 521 Identification of 2,4-diarylaminopyrimidine analogues as ALK inhibitors by using 3D-QSAR, molecular docking, and molecular dynamics simulations. **2017**, 148, 1711-1725
- 520 Targeted Therapies for Lung Cancer. **2018**, 239-255
- 519 Precise, pan-cancer discovery of gene fusions reveals a signature of selection in primary tumors.
- 518 Translocations as Predictive Biomarkers in Lung Cancer. **2018**, 159-171
- 517 Translocation Testing of Lung Cancer Biomarkers. **2018**, 109-118
- 516 PROGNOSTIC SIGNIFICANCE OF REARRANGEMENTS OF EML4-ALK IN PATIENTS WITH STAGE T1-II ADENOCARCINOMA IN THE RELATIONSHIP WITH SOME CLINICAL AND MORPHOLOGICAL PARAMETERS. **2017**, 22, 194-197
- 515 Immunohistochemistry of Lung Cancer Biomarkers. **2018**, 119-130
- 514 Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS). **2018**, 93-108

513 Spectrum of spitzoid neoplasms. **2017**, 14, 149-155

512 5. Present State of Molecular Target Drug for Lung Cancer. **2017**, 106, 1910-1915

511 Gene Fusions. **2018**, 137-151

510 Clinicopathological profile of lung cancer at a tertiary care center. **2018**, 55, 273-275

o

509 Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis. **2018**, 30, 309-315

508 Pathology of Lung Cancer. **2018**, 9-22

507 Serous Effusion Cytology. **2018**, 235-257

506 Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.. **2019**, 8, S48-S54

505 Clinicopathological Profile of Anaplastic Lymphoma Kinase-positive Nonsmall Cell Lung Cancer: An Indian Perspective. **2018**, 39, 32-35

504 Placing Segments on Parallel Arcs. **2018**, 298-310

503 The absence of a novel intron 19-retaining transcript (-I19) and amplification correlates with an excellent clinical outcome in neuroblastoma patients. **2018**, 9, 10698-10713

502 ALK and Others: How Important Are ALK and Other Mutations in the Management of Lung Cancer?. **2018**, 295-315

501 3. Development of Lung Cancer Therapy -Usefulness of Biomarker-based Medicine for Lung Cancer-. **2018**, 107, 86a-90a

500 Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis.

499 The Treatment Strategy for ALK-positive Non-small-cell Lung Carcinoma. **2018**, 58, 258-261

498 Non-small-cell lung cancer (NSCLC) harboring driver mutation (EGFR mutation or ALK translocations) with clinical characteristics and management in a real-life setting: a retrospective observational multicenter case series study. **2018**, 10, 361-367

497 3. Development of Lung Cancer Therapy-Usefulness of Biomarker-based Medicine for Lung Cancer-. **2018**, 107, 1660-1669

496 Treatment of patients with non-small cell lung cancer with ALK rearrangement. **2018**, 12, 182-184

- 495 Molecular Targeted Therapy of Lung Cancer. **2018**, 14, 177-179
- 494 Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target.
- 493 Mitotic phosphorylation by Nek6 and Nek7 reduces microtubule affinity of EML4 to alter spindle dynamics and promote chromosome congression. 0
- 492 Recent Progress and Prospects of Medical Therapy for Lung Cancer. **2018**, 77, 375-378
- 491 Unmet Needs and Future Outlook of Mesothelioma Management. **2019**, 331-340
- 490 Impact of crizotinib on long-term survival of -positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study. **2019**, 31, 481-488 2
- 489 EML4-ALK V3 Drives Cell Migration Through NEK9 and NEK7 Kinases in Non-Small-Cell Lung Cancer.
- 488 Heat Shock Protein 90 Inhibitors in Lung Cancer Therapy. **2019**, 359-395 0
- 487 Lung Molecular Cytopathology: EGFR and Beyond. **2019**, 36, 124-127 1
- 486 Anaplastic Lymphoma Kinase. **2019**, 31-54
- 485 Recent Advances in the au NP Treatment Strategies of Lung Cancers. **2019**, 701-729
- 484 EML4-ALK V3 drives cell migration through NEK9 and NEK7 kinases in non-small-cell lung cancer. 1
- 483 What are the Uncommon Anaplastic Lymphoma Kinase (ALK) Fusions in Non-Small Cell Lung Cancer?. 6,
- 482 Clinically-relevant cell type cross-talk identified from a human lung tumor microenvironment interactome. 1
- 481 Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.. **2019**, 8, 736-751
- 480 Mechanisms of Resistance to Molecular-targeted Drugs in Lung Cancer. **2019**, 59, 224-230
- 479 Improved detection of gene fusions by applying statistical methods reveals new oncogenic RNA cancer drivers.
- 478 Application of International association for the study of lung cancer/American Thoracic Society/European Respiratory Society criteria for the diagnosis of lung carcinomas on small biopsies: A tertiary care center experience. **2019**, 8, 191-194

- 477 Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. 1
- 476 A Case Report of a Multi-cerebral Infarction Associated with Trousseau Syndrome Before the Diagnosis of ALK-positive Lung Adenocarcinoma. **2019**, 59, 384-389 1
- 475 Dual drive coexistence of rearrangement and mutation advanced lung adenocarcinoma and response to crizotinib.. **2019**, 8, 1630-1634
- 474 CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK. **2019**, 19, 655-665 1
- 473 Lung Carcinoma. **2020**, 83-101
- 472 Evolutionary analyses guide selection of model systems to investigate proto-oncogene function in ALK and LTK.
- 471 Lung and Respiratory Tract Cytology. **2020**, 95-117
- 470 Analysis of real-world mutations of lung cancer driver genes in five regions of China.. **2019**, 8, 2581-2592 1
- 469 Pathology of Brain Metastasis. **2020**, 15-29 0
- 468 Genomic Characterization of Brain Metastases: Implications for Precision Medicine. **2020**, 43-58
- 467 Lung Cancer. **2020**, 13-30
- 466 Systemic Therapy of Brain Metastases: Lung Cancer. **2020**, 207-217
- 465 [Epidemiology and diagnosis of mutations in the ALK gene in patients with non-small cell lung cancer in the Moscow region]. **2020**, 82, 18-23
- 464 Biomarkers from Bench to Bedside and Back [Back-Translation of Clinical Studies to Preclinical Models. **2020**, 307-331
- 463 Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
- 462 The biology of Epidermal Growth Factor Receptor (EGFR) from regulating cell cycle to promoting carcinogenesis: the state of art including treatment options. **2020**, 5, 048-053 1
- 461 In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. **2020**, 111, 1887-1898 2
- 460 A Unique Case of a High-Grade Neuroepithelial Tumor With EML4-ALK Fusion in a Five-Month-Old. **2020**, 12, e8654 1

- 459 Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma. **2020**, 164, 127-132
- 458 Role of imaging biomarkers in mutation-driven non-small cell lung cancer. **2020**, 11, 412-427 1
- 457 A Surgical Case of a 15-year-old Girl with EML4-ALK-positive Lung Adenocarcinoma Detected with Roentgenographic Screening. **2020**, 60, 330-334
- 456 Current Status of Translational Research in Lung Cancer and Perspectives and Challenges of Academic Translational Research in Japan. **2020**, 60, 305-313
- 455 Future directions and management of liquid biopsy in non-small cell lung cancer. **2020**, 1, 239-252 1
- 454 The 2019 Incentive Awards of the Okayama Medical Association in Cancer Research (2019 Hayashibara Prize and Yamada Prize). **2020**, 132, 54-56
- 453 Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-). **2022**, 227, 113963 3
- 452 Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report. **2021**, 100, e27611 2
- 451 Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer. **2021**, 22, 1
- 450 Malignant Epithelial Tumors of the Lung. **2020**, 317-400
- 449 Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. **2020**, 125-153
- 448 Crizotinib Wins the Battle against Advanced ALK-Positive NSCLC: A Meta Analysis for Phase 3 and 4 Clinical Trails. **2020**, 10, 724-732
- 447 Testing for Driver Oncogenes is Essential for the Optimal Treatment of Advanced Non-small-cell Lung Cancer. **2020**, 66, 403-409
- 446 The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report. **2021**, 22, 1-4 0
- 445 The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer. **2020**, 9, 2557-2570 1
- 444 Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study. **2021**, 21, 65-78
- 443 Longitudinal health utilities, symptoms and toxicities in patients with rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment. **2020**, 27, e552-e559 2
- 442 Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. **2020**, 9, 2599-2617 0

441	High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. 2020 , 13, 3518-3535	21
440	Gastrointestinal Toxicities of Targeted Therapy. 2020 , 119-132	
439	Appreciation of Pattern in Diagnosis of Lung Adenocarcinoma from Cytology Specimen: Our Experience with Fine Needle Aspiration Cytology and Cell Block in a Resource Constraint Setup. 2020 , 37, 141-146	0
438	Lorlatinib-Associated Acute Respiratory Distress Syndrome. 2020 , 27, e698-e699	1
437	Precision Medicine in Lung Cancer.	
436	A liquid biopsy platform for detecting gene-gene fusions as glioma diagnostic biomarkers and drug targets.	0
435	Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.	
434	Utilidad clínica de la biopsia líquida para el diagnóstico y seguimiento de los pacientes con CPNM y EML4-ALK. 2020 , 1,	
433	Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions. 2021 ,	2
432	Scientific Validation and Clinical Application of Lung Cancer Organoids. 2021 , 10,	1
431	Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report. 2021 , 162, 86-89	0
430	Quantitative volumetric assessment of the solid portion percentage on CT images to predict ROS1/ALK rearrangements in lung adenocarcinomas. 2020 , 20, 2987-2996	1
429	Genome-Scale CRISPR Screening reveals novel factors regulating Wnt-dependent regeneration of mouse gastric organoids.	
428	Experience of using fozotinib in patients with ALKpositive non-small cell lung cancer. 2020 , 176-181	
427	Metastatic Anaplastic Lymphoma Kinase Rearrangement-Positive Adenocarcinoma of Occult Primary Mimicking Ovarian Cancer. 2020 , 12, e9437	1
426	Bimolecule detection for Extracellular Vesicle Screening.	
425	Screening of significant oncogenic changes in air pollution-related lung cancer in Chinese population.. 2020 , 9, 4341-4353	
424	Cancer genomic medicine in Japan. 2020 , 96, 316-321	5

423 The current and future roles of genomics. 79-94

422 Molecular pathology. 95-118

1

421 Achievements in targeted therapies. 215-233

420 Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists. **2020**, 16, 5-10

419 CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS. **2020**, 19, 132-137

418 Alectinib in the treatment of advanced ALK + NSCLC. **2020**, 14, 135-138

417 Molecular genetic portrait of non-small cell lung cancer in Tambov region: regional experience. **2020**, 22, 88-93

416 Irreversible epidermal growth factor receptor inhibitor Z25h exhibits pronounced inhibition on non-small cell lung adenocarcinoma cell line Hcc827. **2021**, 32, 417-426

415 Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience. **2020**, 41, 29-36

1

414 Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer. **2015**, 7, 875-80

10

413 Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer. **2014**, 3, 379-81

5

412 [Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation]. **2011**, 14, 880-4

2

411 Cutaneous metastasis as an initial presentation of lung adenocarcinoma with KRAS mutation: a case report and literature review. **2014**, 1, 6

3

410 Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity. **2009**, 2, 508-18

10

409 Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. **2011**, 36, 263-79

14

408 Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. **2011**, 1, 604-17

26

407 Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. **2012**, 4, 214-6

16

406 ALK-immunoreactive neoplasms. **2012**, 5, 397-410

29

405	EGFR inhibition and more: a new generation growing up. 2012 , 4, 553-5	2
404	FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer. 2013 , 6, 598-612	16
403	Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method. 2012 , 8, 1-6	7
402	Contrast agents for quantitative microCT of lung tumors in mice. 2013 , 63, 482-90	9
401	Absence of anaplastic lymphoma kinase translocations in signet ring cell carcinomas of the upper gastrointestinal tract. 2014 , 7, 39-41	2
400	The biomolecular era for thoracic surgeons: the example of the ESTS Biology Club. 2014 , 6 Suppl 2, S265-71	1
399	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. 2014 , 11, 173-81	19
398	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. 2014 , 12, 429-39	167
397	Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. 2014 , 4, 608-28	19
396	Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy. 2012 , 1, 72-7	3
395	Status quo and prospects of the translational research on lung cancer in China. 2012 , 1, 91-3	
394	Apoptotic agents. 2013 , 2, 238-43	3
393	MET inhibition in lung cancer. 2013 , 2, 23-39	11
392	Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. 2015 , 4, 149-55	17
391	Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements. 2015 , 7, 220-3	3
390	ALK-rearranged squamous cell lung cancer: a case report. 2015 , 8, 2195-8	11
389	Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting in nasal cavity: a case report and review of literature. 2015 , 8, 2123-30	6
388	TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma. 2015 , 8, 2690-9	3

387	Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer. 2015 , 8, 3344-8	2
386	Primary pulmonary adenoid cystic carcinoma: clinicopathological analyses of 12 cases. 2015 , 8, 7619-26	8
385	Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. 2015 , 8, 10330-9	16
384	Notes for developing a molecular test for the full characterization of circulating tumor cells. 2015 , 27, 471-8	1
383	Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning. 2015 , 4, 649-52	2
382	Expression pattern of FGFR2, Grb2 and Plc β 1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. 2015 , 5, 3135-48	9
381	Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform. 2016 , 13, 68-76	4
380	Molecular mechanism underlying the pharmacological interactions of the protein kinase C- β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells. 2017 , 7, 816-830	2
379	Molecular Targets in Non-Small Cell Lung Cancer. 2017 , 17, 388-392	14
378	[Methylation Status of the SOCS3 Gene Promoter in H2228 Cells and ?EML4-ALK-positive Lung Cancer Tissues]. 2016 , 19, 565-70	
377	[Clinical Advanced in Early-stage ALK-positive Non-small Cell Lung Cancer Patients]. 2017 , 20, 124-129	1
376	[Treatment of Patients with ALK-positive Non-small Cell Lung Cancer ?and Brain Metastases]. 2016 , 19, 519-24	1
375	[Association between the ALK Gene Status and the Efficacy of First-line ?Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. 2017 , 20, 732-736	1
374	[Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer]. 2017 , 20, 66-72	
373	[Observation - An Favorable Option Forthoracic Dissemination Patients with Lung Adenocarcinoma or Squamous Carcinoma]. 2018 , 21, 303-309	1
372	[Value of Immunohistochemical Methods in Detecting EML4-ALK Fusion Mutations: A Meta-analysis]. 2016 , 19, 38-45	0
371	[Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC]. 2016 , 19, 161-8	
370	[Crizotinib treatment in a lung adenocarcinoma harboring ALK fusion gene with bone marrow metastasis: case report and literature review]. 2015 , 18, 85-8	2

- 369 [A case report: an EML4-ALK positive lung adenocarcinoma diagnosed with lymphoma previously]. **2015**, 18, 89-91
- 368 [Analysis of EML4-ALK gene fusion mutation in patients with non-small cell lung cancer]. **2015**, 18, 80-4 2
- 367 [Treatment of patients with ALK gene rearranged non-small cell lung cancer after resistance to crizotinib]. **2015**, 18, 69-74
- 366 [Assessment of ALK rearrangement in non-small cell lung cancer: using enhancing immunohistochemical way and fluorescence in situ hybridization]. **2015**, 18, 75-9 1
- 365 [Diagnosis for ALK positive non-small cell lung cancer]. **2015**, 18, 61-8
- 364 [A new target in non-small cell lung cancer: EML4-ALK fusion gene]. **2011**, 14, 538-42 1
- 363 [Methodology of Establishing and Identifying NCI-H2228/Crizotinib-resistant Cell Lines In Vitro]. **2015**, 18, 330-9
- 362 [Analysis of the First Diagnosis Symptom and Its Influencing Factors in 500 Patients with Lung Cancer]. **2018**, 21, 408-412 1
- 361 [Current status and future direction of multi-targeted drugs in the era of personalized therapy--overview of advances in multi-targeted therapy in non-small cell lung cancer]. **2011**, 14, 874-9
- 360 [Significance of immunohistochemical indicators in diagnosis and prognosis of squamous cell carcinoma and adenocarcinoma of lung]. **2014**, 17, 506-10
- 359 [Driver genes and its clinical significance in non-small cell lung cancer]. **2014**, 17, 481-6 0
- 358 [EML4-ALK fusion gene in lung cancer and its biological function]. **2012**, 15, 112-6 2
- 357 [The EML4-ALK fusion gene in NSCLC and the clinical progress]. **2011**, 14, 435-40
- 356 [Research progress of targeted therapy in non-small cell lung cancer brain metastases]. **2014**, 17, 824-8 1
- 355 [The targets research of non-small cell lung cancer targeted therapy]. **2013**, 16, 107-13 0
- 354 [Clinical meaning of EML4-ALK fusion gene in non-small cell lung cancer]. **2013**, 16, 97-101 1
- 353 [Advances on driver oncogenes of lung adenocarcinoma]. **2013**, 16, 91-6 0
- 352 [Current status of targeted therapy for anaplastic lymphoma kinase in non-small cell lung cancer]. **2014**, 17, 850-4

351	[Mechanisms of resistance to EML4-ALK inhibitors in non-small cell lung cancer]. 2013 , 16, 48-53	
350	[Clinical research of crizotinib in advanced non-small cell lung cancer]. 2013 , 16, 321-4	
349	[Clinical significance of ROS1 rearrangements in non-small cell lung cancer]. 2013 , 16, 663-70	
348	[Development of Precision Medicine in the Surgical Treatment of Lung Cancer]. 2016 , 19, 318-20	0
347	[The research of clinical pathological features of ALK positive lung cancer in 525 patients and the discussion of detection methods]. 2014 , 17, 226-32	0
346	Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin. 2018 , 19, 1735-1738	1
345	[Personalized targeted therapy for lung cancer]. 2013 , 16, C21-34	
344	Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met. 2018 , 8, 1541-1550	1
343	[Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer]. 2018 , 21, 703-711	1
342	Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer. 2018 , 9, 94-101	9
341	[MRTF-A Regulates the Proliferation and Migration of Non-small Cell Lung Cancer Cells of A549 through HOTAIR]. 2019 , 22, 82-89	1
340	Clinical applications of liquid biopsies for early lung cancer detection. 2019 , 9, 2567-2579	6
339	Comparison of clinicopathological and molecular features between young and old patients with lung cancer. 2018 , 11, 1031-1035	1
338	[Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI]. 2020 , 23, 381-387	1
337	Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists. 2020 , 9, 2194-2198	1
336	New insights of extrachromosomal DNA in tumorigenesis and therapeutic resistance of cancer. 2020 , 10, 4056-4065	3
335	Precision Medicine: A New Paradigm in Therapeutics. 2021 , 12, 12	0
334	[Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report]. 2021 , 24, 598-604	

333	Recent advances in lung cancer genomics: Application in targeted therapy. 2021 , 108, 201-275	0
332	A Case Report on ROS1-positive Recurrent Non-small-cell Lung Cancer Treated with Crizotinib and Korean Medicine. 2021 , 42, 820-832	0
331	Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL. 2021 , 13,	0
330	The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. 2021 ,	26
329	Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. 2021 , 163, 7-13	0
328	ALK rearrangements in infantile fibrosarcoma-like spindle cell tumors of soft tissue and kidney. 2021 ,	1
327	Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles. 2021 , 3, v35-v42	
326	Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data. 2021 , 12, 2308-2315	0
325	A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer. 2021 ,	5
324	Genetic fusions favor tumorigenesis through degron loss in oncogenes. 2021 , 12, 6704	2
323	The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. <i>Nature</i> , 2021 , 600, 319-323	50.4 7
322	Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib.. 2021 , 11,	2
321	Targeting MERTK and AXL in Mutant Non-Small Cell Lung Cancer. 2021 , 13,	2
320	Mad2 Induced Aneuploidy Contributes to Driven Lung Cancer by Generating an Immunosuppressive Environment. 2021 , 13,	0
319	Discovery of clinically relevant fusions in pediatric cancer. 2021 , 22, 872	2
318	Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. 2021 , 22, 1764-1776	6
317	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than .. 2021 , 11, 750657	4
316	Nicht-kleinzelliges Lungenkarzinom: Wandel und Möglichkeiten der molekularen Diagnostik.	

- 315 Oncologic Rare Disease Drug Development. **2021**, 179-195
- 314 Epidemiological, clinical profile, and treatment outcome of stage iv nonsquamous nonsmall cell lung cancer patients presenting to tertiary care hospital in North India. **2021**, 5, 104
- 313 Prevalence and Clinicopathologic Risk Factors for Epidermal Growth Factor Receptor, Anaplastic Lymphoma Kinase, and ROS-1 Fusion in Metastatic Non-small Cell Lung Carcinoma. **2021**,
- 312 ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.. **2022**, 27, e76-e84 ○
- 311 The anti-programmed cell death 1 antibody immunotherapy: A paradigm shift in the treatment of nonsmall-cell lung cancer. **2020**, 5, 29
- 310 Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists. **2020**, 9, 2194-2198 1
- 309 Chordin-like 1 is a novel prognostic biomarker and correlative with immune cell infiltration in lung adenocarcinoma.. **2022**, 14, 3
- 308 The Extent of Expression of Thyroid Transcription Factor 1, Cytokeratin 7, and Anaplastic Lymphoma Kinase in Lung Adenocarcinoma.. **2022**, 10, 10-14
- 307 Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.. **2022**, 1, CD013453 ○
- 306 A Case of Advanced Non-Small-Cell Lung Cancer With Response to Alectinib and Favorable Quality of Life.. **2022**, 14, e21170
- 305 Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib.. **2022**, 14, 1-9
- 304 NTRK3 gene fusion in an adult ganglioglioma: illustrative case. **2022**, 3,
- 303 El cáncer de pulmón de células no pequeñas en la era de la medicina de precisión. **2022**, 33, 25-35 ○
- 302 Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry.. **2022**, 15, 21-26
- 301 Identification of a Novel Oncogenic Fusion Gene in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells.. **2022**, 23,
- 300 Epstein-Barr Virus Infection in Lung Cancer: Insights and Perspectives.. **2022**, 11, ○
- 299 HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.. **2022**, 6, 5 ○
- 298 Experimental Determination of Cancer Drug Targets with Independent Mechanisms of Resistance.. **2022**,

297	High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare fusion sites: a case report.. 2022 , 11, 100-110	0
296	Experiencia inicial de detección de mutaciones en biopsia tumoral y líquida de pacientes con adenocarcinoma pulmonar. 2022 , 33, 68-74	
295	Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.. 2022 ,	0
294	Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.. 2022 , 7, 25	1
293	Analysis of the effect of NEKs on the prognosis of patients with non-small-cell lung carcinoma based on bioinformatics.. 2022 , 12, 1705	0
292	A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC.. 2022 , 14,	0
291	Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy.. 2022 , 17, 182-185	1
290	ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061).. 2022 , 165, 54-62	0
289	Long-term effects of pharmacological inhibition of Anaplastic lymphoma kinase in Neurofibromatosis 1 mutant mice.. 2022 , 113767	
288	A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.. 2022 , 29, 848-852	0
287	T Lymphocyte Infiltration in Association with IDO1 Expression in Resected Lung Adenocarcinoma and Normal Adjacent Lung Tissues.. 2022 , 2022, 2381018	
286	Current Therapy and Development of Therapeutic Agents for Lung Cancer. 2022 , 100015	1
285	Molecular characterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling.. 2021 , 1-24	3
284	Analysis of the Efficacy of Afatinib in the Treatment of ALK-Positive Squamous Cell Carcinoma. 2022 , 11, 1-5	
283	Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial.. 2022 , 21, 15347354221086663	0
282	Target therapy in cancer treatment. 2022 ,	
281	The oncogenic fusion landscape in pediatric CNS neoplasms.. 2022 , 143, 427	0
280	STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.. 2022 , 6, 11	0

- 279 Dramatic response to crizotinib in a breast cancer patient with ALK gene rearrangement.. **2022**, 33, 0
- 278 Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring Rearrangement: A Case Report.. **2022**, 12, 761558 1
- 277 Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.. **2022**, 14, 2
- 276 Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.. **2022**, 14, 843-850 0
- 275 Anaplastic lymphoma kinase inhibitors and their effect on the kidney. 0
- 274 Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece. **2022**, 9, 50-57 0
- 273 Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. **2022**, 11
- 272 In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.
- 271 Efficacy and Safety of Ceritinib 450 mg/d With Food and 750 mg/d in Fasted State in Treatment-Naïve Patients With ALK+ Non-small Cell Lung Cancer: Results From the ASCEND-8 Asian Subgroup Analysis.. **2022**,
- 270 Cancer Genetics and Genomics - Part 2.. **2022**, 0
- 269 Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?. **2022**, 22, 323 1
- 268 GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.. **2022**, 6, 16 1
- 267 Resected stage I anaplastic lymphoma kinase-positive lung adenocarcinoma has a negative impact on recurrence-free survival.. **2022**,
- 266 Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review. 0
- 265 Utilizing CRISPR/Cas9 Technologies for in vivo Disease Modeling and Therapy. **2022**, 93-110
- 264 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study.. **2022**, 13, 858279 2
- 263 Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.. **2022**, 166, 170-177 0
- 262 Construction of a Two-Gene Immunogenomic-Related Prognostic Signature in Lung Squamous Cell Carcinoma.. **2022**, 9, 867494

261	A Genome-Wide Gene-Based GeneEnvironment Interaction Study of Breast Cancer in More than 90,000 Women. 2022 , 2, 211-219	0
260	Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes.. 2022 , 7, 100405	0
259	Targeting ALK Rearrangements in NSCLC: Current State of the Art.. 2022 , 12, 863461	1
258	Survival after Recurrence following Surgical Resected Non-small Cell Lung Cancer: A Multicenter, Prospective Cohort Study. 2022 ,	0
257	Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.. 2022 , 166, 51-59	0
256	Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. 2021 , 21, 1322	1
255	Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.. 2021 , 100, e27999	
254	Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel Fusion Lung Adenocarcinoma: A Case Report.. 2021 , 14, 5471-5475	0
253	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.. 2021 , 2, 692-729	2
252	The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management.. 2021 , 21, 675	1
251	Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience. 2021 , 62-67	
250	New Proteins Contributing to Immune Cell Infiltration and Pannus Formation of Synovial Membrane from Arthritis Diseases.. 2021 , 23,	2
249	Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.. 2021 ,	1
248	The Main Objective of Antitumor Targeted Therapy in Lung Cancer. 2020 , 72-76	
247	A CRISPR-Cas9-Based Therapeutics in Oxidative Stress-Induced Cancer. 2022 , 1-18	
246	Current trends in chemotherapy for advanced ovarian cancer.. 2022 ,	
245	Role of in -positive non-small cell lung cancer.. 2022 , 23, 181	
244	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.. 2022 , 101950	0

- 243 Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types.. **2022**, 12, 6345 ○
- 242 Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma.. **2022**,
- 241 A Hypoxia-Related Signature for Predicting Prognosis, Cellular Processes, Immune Microenvironment and Targeted Compounds in Lung Squamous Cell Carcinoma.. **2022**, 15, 3991-4006
- 240 ALK Translocation in ALK-Positive Mesenchymal Tumors.. **2022**,
- 239 Molecular Diagnostics of Lung Cancer in Serous Effusion Samples. **2022**, 3, 78-87 ○
- 238 Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations.. **2022**, 128730 ○
- 237 Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. 499-517
- 236 MOLECULAR GENETICS OF SOFT TISSUE TUMORS. 127-180
- 235 Table_1.xlsx. **2019**,
- 234 Table_2.docx. **2019**,
- 233 Table_3.xlsx. **2019**,
- 232 Data_Sheet_1.PDF. **2019**,
- 231 Data_Sheet_2.PDF. **2019**,
- 230 Image_1.TIF. **2019**,
- 229 Table_1.XLSX. **2019**,
- 228 Table_2.XLSX. **2019**,
- 227 Table_3.XLSX. **2019**,
- 226 Image_1.tif. **2020**,

225 Image_2.tif. **2020**,

224 Image_3.tif. **2020**,

223 Image_4.tif. **2020**,

222 Image_5.tif. **2020**,

221 Image_6.tif. **2020**,

220 Table_1.xlsx. **2020**,

219 Table_2.xlsx. **2020**,

218 Table_3.xlsx. **2020**,

217 Table_4.xlsx. **2020**,

216 Table_5.xlsx. **2020**,

215 Data_Sheet_1.docx. **2020**,

214 Data_Sheet_1.docx. **2019**,

213 Table_1.XLSX. **2019**,

212 Data_Sheet_1.pdf. **2018**,

211 Data_Sheet_1.PDF. **2020**,

210 Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC.. **2022**, 8, 221

209 A functional genomic approach to actionable gene fusions for precision oncology.. **2022**, 8, eabm2382

208 [Recommendations from Experts in the Management of Adverse Reactions ?to ALK Inhibitors (2021 Version)]. **2021**,

- 207 Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer.. **2022**, 16, 11795549221092747 0
- 206 Research Progress on Small Molecules Targeted Therapy in Non-Small Cell Lung Cancer. **2022**, 12, 90-98 0
- 205 Integrated analysis of ALK higher expression in human cancer and downregulation in LUAD using RNA molecular scissors.. **2022**, 0
- 204 SMYD Protein Family as Promising Biomarkers for Cancer Diagnosis and Prognosis. **2022**, 273-307
- 203 The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs). **2022**, 12, 0
- 202 Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.. **2022**,
- 201 Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.. **2022**, 2
- 200 Impact of compound mutations I1171N + F1174I and I1171N + L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights.. **2022**, 1-9 0
- 199 The translational challenges of precision oncology.. **2022**, 3
- 198 Discovery of 2,4-diarylamino-pyrimidine derivatives bearing dithiocarbamate moiety as novel ALK inhibitors.. **2022**, 66, 116794
- 197 Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer. **2022**, 13,
- 196 Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.. **2022**, 14, 0
- 195 The Current State of Precision Medicine and Targeted-Cancer Therapies: Where Are We?. **2022**, 119-200
- 194 Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced non-small-cell lung cancer patients with ALK fusion in China.. **2022**,
- 193 Predictive Biomarkers for Anticancer Drugs. **2022**, 149-176
- 192 Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. **2022**, 0
- 191 LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report. **2022**, 12,
- 190 Identification of the Putative Tumor Suppressor Characteristics of FAM107A via Pan-Cancer Analysis. **2022**, 12,

- 189 The regulation of CD73 in non-small cell lung cancer. **2022**, 170, 91-102 1
- 188 EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity. **2022**, 20, 854-866 1
- 187 Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
- 186 Multiple Primary Lung Cancers With ALK Rearrangement: A Case Report and Literature Review. 12,
- 185 Prediction of Resistant Mutations against Upcoming ALK-TKIs, Repotrectinib (TPX-0005) and Ensartinib (X-396).
- 184 Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC. **2022**, 20, 0
- 183 The Prognostic Model and Drug Sensitivity of LKB1-Mutant Lung Adenocarcinoma Based on Immune Landscape. **2022**, 9,
- 182 Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy. 1-20
- 181 Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?. **2022**, 13, 800-809
- 180 Immunohistochemistry: Roche Tissue Diagnostics Perspective. **2022**, 77-85
- 179 A Rare Case of Pulmonary Anaplastic Lymphoma Kinase Positive Signet Ring Cell Carcinoma in a Japanese Male.
- 178 CATCH: high specific transcriptome-focused fusion gene variants discrimination. 1
- 177 Management of Combined Therapy (Ceritinib, A. cinnamomea, G. lucidum, and Photobiomodulation) in Advanced Non-Small-Cell Lung Cancer: A Case Report. **2022**, 12, 862
- 176 Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. **2022**, 13, 812-827
- 175 Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer. **2022**, 102430 1
- 174 Targeting molecular alterations in non-small-cell lung cancer: what's next?. 0
- 173 EML4-ALK fusion gene in non-small cell lung cancer (Review). **2022**, 24, 1
- 172 Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions. 12,

171	Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.	0
170	Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective. 2022 , 14, 2912	1
169	Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer. 13,	0
168	Long-term treatment with ALK inhibitors for postoperative recurrence of ALK-rearranged lung cancer.	0
167	Phasing analysis of lung cancer genomes using a long read sequencer. 2022 , 13,	1
166	Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. 2022 , 21,	2
165	EGFR, NF- κ B and noncoding RNAs in precision medicine. 2022 ,	
164	The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation. 2022 , 23, 7322	
163	Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles. 2022 ,	
162	Fbxo45-mediated NP-STEP 46 degradation via K6-linked ubiquitination sustains ERK activity in lung cancer.	0
161	Primary pulmonary epithelioid inflammatory myofibroblastic sarcoma: a rare entity and a literature review. 2022 , 56, 231-237	0
160	Unplanned pregnancy in an HIV positive woman undergoing alectinib treatment for metastatic non-small-cell lung carcinoma. 2022 , 15, e247530	0
159	Integrated analysis of the clinical consequence and associated gene expression of ALK in ALK-positive human cancers. 2022 , 8, e09878	
158	Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. 2022 , 14, 3452	1
157	Molecular biomarkers and liquid biopsies in lung cancer. 2022 ,	0
156	Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).	0
155	Leptomeningeal Metastases: New Opportunities in the Modern Era.	1
154	Lorlatinib as a treatment for ALK-positive lung cancer. 2022 , 18, 2745-2766	0

- 153 Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations. **2022**, 23, 101471
- 152 Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases. 12, ○
- 151 Novel read-through fusion transcript Bcl2l2-Pabpn1 in glioblastoma cells. ○
- 150 Novel Human-derived EML4-ALK Fusion Cell Lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. **2022**,
- 149 Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer. 13, 1
- 148 Boosting anti-tumor immunity with an expanded neoepitope landscape.
- 147 Role of Tepotinib, Capmatinib and Crizotinib in non-small cell lung cancer. 6, 321-327
- 146 Overexpression of 14-3-3 β primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC. **2022**, 14, 5838-5854 1
- 145 Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies. **2022**,
- 144 Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma. **2022**, 14, 3671
- 143 Identification of novel prognostic risk signature of breast cancer based on ferroptosis-related genes. **2022**, 12, ○
- 142 Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients. ○
- 141 Protein Lysine Methyltransferase SMYD2: A Promising Small Molecule Target for Cancer Therapy. **2022**, 65, 10119-10132 ○
- 140 DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy. 1
- 139 Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
- 138 Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. **2022**, 13, 1
- 137 Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Impact on Survival in Asian Patients. **2022**, ○
- 136 The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine. 12, ○

- 135 Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2. 9,
- 134 Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. **2022**, 1
- 133 Radiomic-signature changes after early treatment improve the prediction of progression-free survival in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. 028418512211196
- 132 Panel Sequencing for Targeted Therapy Selection in Solid Tumors. **2022**,
- 131 A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis. Publish Ahead of Print, 0
- 130 Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report. **2022**, 101, e30094 0
- 129 Profiling of gene fusion involving targetable genes in Chinese gastric cancer. **2022**, 14, 1528-1539
- 128 First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. **2022**, 173, 238-249
- 127 Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors. **2022**, 241, 114626
- 126 Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences. **2022**, 174, 200-211 1
- 125 Confirmation of lung adenocarcinoma as the primary cancer with detection of EML4-ALK rearrangement using next-generation sequencing: a case study. **2022**, 238, 154105 0
- 124 Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). **2022**, 173, 83-93 0
- 123 Guide to studying intrinsically disordered proteins by high-speed atomic force microscopy. **2022**, 207, 44-56 1
- 122 Understanding the Molecular Kinetics in NSCLC Through Computational Method. **2022**, 129-163 0
- 121 RBM15 condensates modulate m6A modification of STYK1 to promote tumorigenesis. **2022**, 20, 4825-4836 0
- 120 Targeted Therapies in Non-small Cell Lung Cancer. **2022**, 1
- 119 MagPure chip: an immunomagnetic-based microfluidic device for high purification of circulating tumor cells from liquid biopsies. 1
- 118 Introduction of medical genomics and clinical informatics integration for p-Health care. **2022**, 1-37 1

117	A CRISPR-Cas9-Based Therapeutics in Oxidative Stress-Induced Cancer. 2022 , 3383-3400	0
116	????????????RNA. 2022 ,	0
115	Clinical trial design in the era of precision medicine. 2022 , 14,	3
114	Age does matter in adolescents and young adults vs. older adults with lung adenocarcinoma: A retrospective analysis comparing clinical characteristics and outcomes in response to systematic treatments. 2022 , 24,	0
113	Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report. 2022 , 101, e30255	0
112	Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer. 2022 , 100406	0
111	Non-small cell lung cancer in China.	3
110	Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer. 2022 , 37, 2512-2529	0
109	Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC. 2022 , 13,	0
108	Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models. 2022 , 39,	0
107	Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1 / HER3 activation in ALK-rearranged lung cancer.	0
106	Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study. 2022 , 114, 278-287	0
105	Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor. 2022 , 65, 12427-12444	0
104	Artificial IntelligencePowered Prediction of ALK Gene Rearrangement in Patients With NonSmall-Cell Lung Cancer. 2022 ,	0
103	Comparison between Immunocytochemistry, FISH and NGS for ALK and ROS1 Rearrangement Detection in Cytological Samples. 2022 , 23, 10556	2
102	ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. 2022 , 12, e060782	1
101	ALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3. 2022 , 41, 4547-4559	0
100	The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives. 2022 , 14, 4765	1

- 99 Case Report of CCDC149-ALK fusion: a novel genetic alteration and a clinically relevant target in metastatic papillary thyroid carcinoma. ○
- 98 Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors. ○
- 97 Adaptive Resistance to Lorlatinib via EGFR Signaling in ALK-rearranged Lung Cancer. ○
- 96 ALK -rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors. ○
- 95 Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules. ○
- 94 Chromosomal Aberrations in Cancer. 1-19 ○
- 93 Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells. ○
- 92 Adenocarcinomas of the Lung and Neurotrophin System: A Review. **2022**, 10, 2531 ○
- 91 Molecular Biology, Genetics, and Translational Models of Human Cancer. 1-34 ○
- 90 Cancer Genomics and Evolution. 1-30 ○
- 89 Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing. **2022**, 12, 1684 ○
- 88 Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. **2022**, 15, 1 ○
- 87 Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives. **2022**, 11, 3200 ○
- 86 Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples. 582-597 ○
- 85 Les patients ALK et ROS1 : quelle séquence ?. **2022**, 14, 2S178-2S188 ○
- 84 Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches. **2022**, 19, 14324 ○
- 83 Design and synthesis of boron-containing ALK inhibitor with favorable in vivo efficacy. **2022**, 75, 117071 ○
- 82 Drug Resistance in Lung Cancer. **2022**, ○

81	A clinician's guide to bioinformatics for next-generation sequencing. 2022,	0
80	Local Therapy for Oligometastatic Disease—Start Before the Horse?. 2022, 114, 836-839	0
79	Targeting Gatekeeper Mutations for Kinase Drug Discovery.	1
78	Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study. 2023, 270-271, 32-38	0
77	Eficacia de los inhibidores de ALK en dos casos con evaluación positiva por inmunohistoquímica y negativa por FISH. 2017, 22,	0
76	BCL6-SPECC1L: A Novel Fusion Gene in Nasopharyngeal Carcinoma. 2022, 21, 153303382211399	0
75	Primary Signet-Ring Cell Carcinoma of the Lung: A Case Report: Diagnosis, Treatment and Literature Report. 2022, 12, 10418-10422	0
74	Pathological complete remission in ALK-positive lung cancer patient after multiple lines of conversion therapy. 12,	0
73	PI3K inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer.	0
72	Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. 2022, 20,	0
71	Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report. 13,	0
70	PROTAC therapy as a new targeted therapy for lung cancer. 2022,	0
69	Identification of the Transcriptional Regulatory Role of RUNX2 by Network Analysis in Lung Cancer Cells. 2022, 10, 3122	0
68	Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. 2022, 14, 6101	0
67	Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib. 2022,	0
66	Inversions on human chromosomes.	0
65	Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging. 2022, 15, 1568	0
64	Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. 2022, 27, 8828	1

- 63 Ultrafast prediction of somatic structural variations by filtering out reads matched to pan-genome k-mer sets. ○
- 62 Inferencing Bulk Tumor and Single-Cell Multi-Omics Regulatory Networks for Discovery of Biomarkers and Therapeutic Targets. **2023**, 12, 101 ○
- 61 novoRNABreak: local assembly for novel splice junction and fusion transcript detection from RNA-seq data. ○
- 60 An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer. ○
- 59 Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases. ○
- 58 Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer. ○
- 57 Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance. ○
- 56 Current status and challenges of immunotherapy in ALK rearranged NSCLC. 12, ○
- 55 Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. **2022**, 3, ○
- 54 Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer. ○
- 53 Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. **2022**, ○
- 52 Targeting Oncogenic Driver Mutations in Lung Cancer. **2023**, ○
- 51 Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country. Volume 15, 31-41 ○
- 50 Functional and regulatory impact of chimeric RNAs in human normal and cancer cells. 1
- 49 Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. **2023**, 13, 167 1
- 48 Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology. **2023**, 15, 560 ○
- 47 Visible-Light-Active Coumarin- and Quinolinone-Based Photocatalysts and Their Applications in Chemical Transformations. ○
- 46 Discovery of the GSH responsive α -PROTACs targeting ALK and CDK4/6 as a potential treatment for cancer. **2023**, 248, 115082 ○

- 45 The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naïve ALK-positive non-small cell lung cancer from a US perspective. **2022**, 28, 970-979 ○
- 44 Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). **2023**, 15, 204 ○
- 43 Lungenkarzinom. **2023**, 1-16 ○
- 42 Gene Complexity and Clinical Outcomes of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Chinese Patients: A Retrospective Study. ○
- 41 Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards. **2023**, ○
- 40 Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer. **2023**, 7, ○
- 39 Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review. Publish Ahead of Print, ○
- 38 Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase Inhibitors. 2205262 ○
- 37 Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition; Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene. **2023**, ○
- 36 Catalytic Degradors Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions. ○
- 35 Comparative efficacy and rankings of therapeutics for ALK-positive non-small cell lung cancer with brain metastasis: Updated results from a Bayesian network analysis based on randomized controlled trials. **2023**, 191, 106748 ○
- 34 First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews. **2023**, 34, 294-301 ○
- 33 Frequently mutated genes in predicting the relapse of stage I lung adenocarcinoma. ○
- 32 Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules. 107815522311553 ○
- 31 Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis. **2023**, 129, 1261-1275 ○
- 30 A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma. **2023**, 23, ○
- 29 The safety profile of EGFR/ALK-TKIs administered immediately before or after ICIs in advanced NSCLC. **2023**, 116, 109787 ○
- 28 Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide. 11, ○

- 27 ALK-positive lung cancer: a moving target. **2023**, 4, 330-343 ○
- 26 Long-Read Whole-Genome Sequencing Using a Nanopore Sequencer and Detection of Structural Variants in Cancer Genomes. **2023**, 177-189 ○
- 25 Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement. **2023**, 23, ○
- 24 The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases. 13, ○
- 23 MicroRNA in lung cancer— novel potential way for early diagnosis and therapy. ○
- 22 Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). **2023**, 21, ○
- 21 LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC. **2023**, 4, 100490 ○
- 20 Enhancer co-amplification and hijacking promote oncogene expression in liposarcoma. ○
- 19 Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer. ○
- 18 Precision Surgery in NSCLC. **2023**, 15, 1571 ○
- 17 Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. **2023**, 184, 103954 ○
- 16 The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. **2023**, 1-32 ○
- 15 Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications. **2023**, 184, 103966 ○
- 14 Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report. 13, ○
- 13 Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs. **2023**, 24, 5821 ○
- 12 Mutation Status Analysis Of 58 Patients With Advanced ALK Fusion Gene Positive Non Small Cell Lung Cancer. ○
- 11 Onionin A inhibits small-cell lung cancer proliferation through suppressing STAT3 activation induced by macrophages-derived IL-6 and cell-cell interaction with tumor-associated macrophage. **2023**, 36, 1068-1080 ○
- 10 ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report. **2023**, ○

- 9 Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib. 13, ○
- 8 Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC. ○
- 7 Case reports of patients with ALK-positive NSCLC and brain metastases. **2023**, 17, 57-61 ○
- 6 Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. **2023**, 15, 1252 ○
- 5 A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer. **2023**, 40, ○
- 4 Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. **2023**, 16, 614 ○
- 3 ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells. **2023**, 379, 110516 ○
- 2 New perspectives for targeting therapy in ALK-positive human cancers. ○
- 1 From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. **2023**, 187, 104019 ○